Available
| ID: CHEMBL1476898 | Study: DrugMatrix | Cell Type: kidney | Dose: 167.0 mg/kg | Time: 6 h (+)-Artemisinin | ID: CHEMBL269671 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 1 d (+)-Artemisinin | ID: CHEMBL269671 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d (+)-Artemisinin | ID: CHEMBL269671 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 5 d (6-Methoxy-2-Naphthyl)Acetic Acid | ID: CHEMBL1105 | Study: DrugMatrix | Cell Type: kidney | Dose: 360.0 mg/kg | Time: 6 h (6-Methoxy-2-Naphthyl)Acetic Acid | ID: CHEMBL1105 | Study: DrugMatrix | Cell Type: kidney | Dose: 360.0 mg/kg | Time: 5 d (S)-(-)-Sulpiride | ID: CHEMBL267044 | Study: DrugMatrix | Cell Type: heart | Dose: 1200.0 mg/kg | Time: 1 d (S)-(-)-Sulpiride | ID: CHEMBL267044 | Study: DrugMatrix | Cell Type: heart | Dose: 1200.0 mg/kg | Time: 3 d (S)-(-)-Sulpiride | ID: CHEMBL267044 | Study: DrugMatrix | Cell Type: heart | Dose: 1200.0 mg/kg | Time: 5 d (S)-(-)-Sulpiride | ID: CHEMBL267044 | Study: DrugMatrix | Cell Type: muscle | Dose: 1200.0 mg/kg | Time: 3 d (S)-(-)-Sulpiride | ID: CHEMBL267044 | Study: DrugMatrix | Cell Type: muscle | Dose: 1200.0 mg/kg | Time: 5 d (S)-Fenfluramine | ID: CHEMBL248702 | Study: DrugMatrix | Cell Type: heart | Dose: 29.0 mg/kg | Time: 1 d 1,1-Dichloroethene | ID: CHEMBL156455 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 1 d 1,1-Dichloroethene | ID: CHEMBL156455 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 3 d 1,1-Dichloroethene | ID: CHEMBL156455 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 5 d 1,4-Dichlorobenzene | ID: CHEMBL190982 | Study: DrugMatrix | Cell Type: heart | Dose: 900.0 mg/kg | Time: 1 d 1,4-Dichlorobenzene | ID: CHEMBL190982 | Study: DrugMatrix | Cell Type: heart | Dose: 900.0 mg/kg | Time: 3 d 1,4-Dichlorobenzene | ID: CHEMBL190982 | Study: DrugMatrix | Cell Type: heart | Dose: 900.0 mg/kg | Time: 5 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 2 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 8 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 2 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 8 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 2 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 8 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 4 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 8 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 15 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 29 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 4 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 8 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 15 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 29 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 166.67 μM | Time: 16 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 166.67 μM | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: kidney | Dose: 30.0 mg/kg | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: kidney | Dose: 30.0 mg/kg | Time: 3 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 3 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 7 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 6 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 3 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 7 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 6 h 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 1 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 3 d 1-Naphthyl Isothiocyanate | ID: CHEMBL1381098 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 7 d 10H-Phenothiazine | ID: CHEMBL828 | Study: DrugMatrix | Cell Type: liver | Dose: 36.0 mg/kg | Time: 6 h 10H-Phenothiazine | ID: CHEMBL828 | Study: DrugMatrix | Cell Type: liver | Dose: 36.0 mg/kg | Time: 1 d 10H-Phenothiazine | ID: CHEMBL828 | Study: DrugMatrix | Cell Type: liver | Dose: 386.0 mg/kg | Time: 6 h 10H-Phenothiazine | ID: CHEMBL828 | Study: DrugMatrix | Cell Type: liver | Dose: 386.0 mg/kg | Time: 1 d 10H-Phenothiazine | ID: CHEMBL828 | Study: DrugMatrix | Cell Type: liver | Dose: 386.0 mg/kg | Time: 5 d 2'-Beta-Fluoro-2',3'-Deoxyadenosine | ID: CHEMBL309579 | Study: DrugMatrix | Cell Type: heart | Dose: 7.5 mg/kg | Time: 1 d 2'-Beta-Fluoro-2',3'-Deoxyadenosine | ID: CHEMBL309579 | Study: DrugMatrix | Cell Type: heart | Dose: 7.5 mg/kg | Time: 3 d 2'-Beta-Fluoro-2',3'-Deoxyadenosine | ID: CHEMBL309579 | Study: DrugMatrix | Cell Type: heart | Dose: 7.5 mg/kg | Time: 5 d 2,3,7,8-Tetrachlorodibenzodioxine | ID: CHEMBL30327 | Study: DrugMatrix | Cell Type: liver | Dose: 0.02 mg/kg | Time: 1 d 2,3,7,8-Tetrachlorodibenzodioxine | ID: CHEMBL30327 | Study: DrugMatrix | Cell Type: liver | Dose: 0.02 mg/kg | Time: 3 d 2,3,7,8-Tetrachlorodibenzodioxine | ID: CHEMBL30327 | Study: DrugMatrix | Cell Type: liver | Dose: 0.02 mg/kg | Time: 5 d 2-Amino-4-Nitrophenol | ID: CHEMBL316992 | Study: DrugMatrix | Cell Type: kidney | Dose: 625.0 mg/kg | Time: 1 d 2-Amino-4-Nitrophenol | ID: CHEMBL316992 | Study: DrugMatrix | Cell Type: kidney | Dose: 625.0 mg/kg | Time: 3 d 2-Amino-4-Nitrophenol | ID: CHEMBL316992 | Study: DrugMatrix | Cell Type: kidney | Dose: 625.0 mg/kg | Time: 5 d 3,3',4',5-Tetrachlorosalicylanilide | ID: CHEMBL291338 | Study: DrugMatrix | Cell Type: liver | Dose: 5.0 mg/kg | Time: 6 h 3,3',4',5-Tetrachlorosalicylanilide | ID: CHEMBL291338 | Study: DrugMatrix | Cell Type: liver | Dose: 5.0 mg/kg | Time: 1 d 3-Methylcholanthrene | ID: CHEMBL40583 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 23.0 μM | Time: 16 h 3-Methylcholanthrene | ID: CHEMBL40583 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 23.0 μM | Time: 1 d 3-Methylcholanthrene | ID: CHEMBL40583 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 1 d 3-Methylcholanthrene | ID: CHEMBL40583 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 3 d 3-Methylcholanthrene | ID: CHEMBL40583 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 5 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: heart | Dose: 2.7 mg/kg | Time: 1 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: heart | Dose: 2.7 mg/kg | Time: 3 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: heart | Dose: 2.7 mg/kg | Time: 5 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.7 mg/kg | Time: 1 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.7 mg/kg | Time: 3 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.7 mg/kg | Time: 5 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: liver | Dose: 2.7 mg/kg | Time: 1 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: liver | Dose: 2.7 mg/kg | Time: 3 d 4'-Epidoxorubicin | ID: CHEMBL1237042 | Study: DrugMatrix | Cell Type: liver | Dose: 2.7 mg/kg | Time: 5 d 4,4'-Diaminodiphenylmethane | ID: CHEMBL85728 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 296.0 μM | Time: 16 h 4,4'-Diaminodiphenylmethane | ID: CHEMBL85728 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 296.0 μM | Time: 1 d 4,4'-Diaminodiphenylmethane | ID: CHEMBL85728 | Study: DrugMatrix | Cell Type: liver | Dose: 81.0 mg/kg | Time: 1 d 4,4'-Diaminodiphenylmethane | ID: CHEMBL85728 | Study: DrugMatrix | Cell Type: liver | Dose: 81.0 mg/kg | Time: 3 d 4,4'-Diaminodiphenylmethane | ID: CHEMBL85728 | Study: DrugMatrix | Cell Type: liver | Dose: 81.0 mg/kg | Time: 5 d 4-Aminosalicylic Acid | ID: CHEMBL1169 | Study: DrugMatrix | Cell Type: liver | Dose: 2337.0 mg/kg | Time: 1 d 4-Aminosalicylic Acid | ID: CHEMBL1169 | Study: DrugMatrix | Cell Type: liver | Dose: 2337.0 mg/kg | Time: 5 d 4-Chloro-3,5-Dimethylphenol | ID: CHEMBL398440 | Study: DrugMatrix | Cell Type: liver | Dose: 1915.0 mg/kg | Time: 3 d 4-Nitrobenzoic Acid | ID: CHEMBL101263 | Study: DrugMatrix | Cell Type: kidney | Dose: 1470.0 mg/kg | Time: 1 d 4-Nitrobenzoic Acid | ID: CHEMBL101263 | Study: DrugMatrix | Cell Type: kidney | Dose: 1470.0 mg/kg | Time: 3 d 4-Nitrobenzoic Acid | ID: CHEMBL101263 | Study: DrugMatrix | Cell Type: kidney | Dose: 1470.0 mg/kg | Time: 5 d 4-Nonylphenol | ID: CHEMBL153062 | Study: DrugMatrix | Cell Type: kidney | Dose: 200.0 mg/kg | Time: 1 d 4-Nonylphenol | ID: CHEMBL153062 | Study: DrugMatrix | Cell Type: kidney | Dose: 200.0 mg/kg | Time: 5 d 6-Azauridine | ID: CHEMBL564201 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 1 d 6-Azauridine | ID: CHEMBL564201 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 3 d 6-Azauridine | ID: CHEMBL564201 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Acarbose | ID: CHEMBL1566 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 2 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 8 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Acetamidofluorene | ID: CHEMBL311469 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Acetamidofluorene | ID: CHEMBL311469 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 3 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 2 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 8 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 2 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 8 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 2 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 8 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 2 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 8 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 2 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 8 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 3 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 6 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 9 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Acetaminophen | ID: CHEMBL112 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1950.0 μM | Time: 16 h Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1950.0 μM | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 6 h Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 3 d Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: kidney | Dose: 486.0 mg/kg | Time: 1 d Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: kidney | Dose: 486.0 mg/kg | Time: 3 d Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: kidney | Dose: 486.0 mg/kg | Time: 5 d Acetaminophen | ID: CHEMBL112 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 5 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 2 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 8 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 2 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 8 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 3 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 6 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 9 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 3 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 6 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 9 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 3 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 6 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 9 h Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 1 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Acetazolamide | ID: CHEMBL20 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Acetazolamide | ID: CHEMBL20 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 6 h Aconitine | ID: CHEMBL2103747 | Study: DrugMatrix | Cell Type: heart | Dose: 0.9 mg/kg | Time: 1 d Acrolein | ID: CHEMBL721 | Study: DrugMatrix | Cell Type: heart | Dose: 20.0 mg/kg | Time: 1 d Acrolein | ID: CHEMBL721 | Study: DrugMatrix | Cell Type: heart | Dose: 20.0 mg/kg | Time: 3 d Acrolein | ID: CHEMBL721 | Study: DrugMatrix | Cell Type: heart | Dose: 20.0 mg/kg | Time: 5 d Acrolein | ID: CHEMBL721 | Study: DrugMatrix | Cell Type: kidney | Dose: 20.0 mg/kg | Time: 1 d Acrolein | ID: CHEMBL721 | Study: DrugMatrix | Cell Type: kidney | Dose: 20.0 mg/kg | Time: 3 d Acrolein | ID: CHEMBL721 | Study: DrugMatrix | Cell Type: kidney | Dose: 20.0 mg/kg | Time: 5 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 2 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 8 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 2 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 2 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 75.0 μM | Time: 2 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 75.0 μM | Time: 8 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 75.0 μM | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Adapin | ID: CHEMBL1628227 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Aflatoxin B1 | ID: CHEMBL1697694 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 3 d Aflatoxin B1 | ID: CHEMBL1697694 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 5 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Ajmaline | ID: CHEMBL86872 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Albendazole | ID: CHEMBL1483 | Study: DrugMatrix | Cell Type: liver | Dose: 62.0 mg/kg | Time: 6 h Albendazole | ID: CHEMBL1483 | Study: DrugMatrix | Cell Type: liver | Dose: 62.0 mg/kg | Time: 1 d Albendazole | ID: CHEMBL1483 | Study: DrugMatrix | Cell Type: liver | Dose: 62.0 mg/kg | Time: 3 d Aldosterone | ID: CHEMBL273453 | Study: DrugMatrix | Cell Type: heart | Dose: 0.065 mg/kg | Time: 1 d Aldosterone | ID: CHEMBL273453 | Study: DrugMatrix | Cell Type: heart | Dose: 0.065 mg/kg | Time: 5 d Alendronic Acid | ID: CHEMBL870 | Study: DrugMatrix | Cell Type: heart | Dose: 138.0 mg/kg | Time: 1 d All-Trans-Retinoic Acid | ID: CHEMBL38 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 156.0 μM | Time: 16 h All-Trans-Retinoic Acid | ID: CHEMBL38 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 156.0 μM | Time: 1 d All-Trans-Retinoic Acid | ID: CHEMBL38 | Study: DrugMatrix | Cell Type: kidney | Dose: 7.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.6 μM | Time: 2 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.6 μM | Time: 8 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.6 μM | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 2 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 8 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 2 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 8 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.6 μM | Time: 2 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.6 μM | Time: 8 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.6 μM | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 28.0 μM | Time: 2 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 28.0 μM | Time: 8 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 28.0 μM | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 2 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 8 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 3 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 6 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 9 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 3 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 6 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 9 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 3 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 6 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 9 h Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Allopurinol | ID: CHEMBL1467 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Allopurinol | ID: CHEMBL1467 | Study: DrugMatrix | Cell Type: kidney | Dose: 175.0 mg/kg | Time: 1 d Allopurinol | ID: CHEMBL1467 | Study: DrugMatrix | Cell Type: kidney | Dose: 175.0 mg/kg | Time: 3 d Allopurinol | ID: CHEMBL1467 | Study: DrugMatrix | Cell Type: kidney | Dose: 175.0 mg/kg | Time: 5 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.8 μM | Time: 2 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.8 μM | Time: 8 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.8 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 2 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 8 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 2 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 8 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.8 μM | Time: 2 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.8 μM | Time: 8 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.8 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.0 μM | Time: 2 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.0 μM | Time: 8 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.0 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 70.0 μM | Time: 2 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 70.0 μM | Time: 8 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 70.0 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 3 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 6 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 9 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Allyl Alcohol | ID: CHEMBL234926 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 20.0 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 30.0 μM | Time: 16 h Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 30.0 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 40.0 μM | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: kidney | Dose: 16.0 mg/kg | Time: 3 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: kidney | Dose: 25.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: kidney | Dose: 25.0 mg/kg | Time: 3 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 6 h Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 3 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 5 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 7 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 25.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 25.0 mg/kg | Time: 3 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 25.0 mg/kg | Time: 7 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 32.0 mg/kg | Time: 1 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 32.0 mg/kg | Time: 3 d Allyl Alcohol | ID: CHEMBL234926 | Study: DrugMatrix | Cell Type: liver | Dose: 32.0 mg/kg | Time: 5 d Alpha-Naphthoflavone | ID: CHEMBL283196 | Study: DrugMatrix | Cell Type: liver | Dose: 80.0 mg/kg | Time: 5 d Amantadine | ID: CHEMBL660 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1500.0 μM | Time: 16 h Amantadine | ID: CHEMBL660 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1500.0 μM | Time: 1 d Amantadine | ID: CHEMBL660 | Study: DrugMatrix | Cell Type: liver | Dose: 220.0 mg/kg | Time: 1 d Amikacin | ID: CHEMBL177 | Study: DrugMatrix | Cell Type: kidney | Dose: 82.0 mg/kg | Time: 1 d Amikacin | ID: CHEMBL177 | Study: DrugMatrix | Cell Type: kidney | Dose: 160.0 mg/kg | Time: 5 d Amikacin | ID: CHEMBL177 | Study: DrugMatrix | Cell Type: kidney | Dose: 160.0 mg/kg | Time: 14 d Amiloride | ID: CHEMBL945 | Study: DrugMatrix | Cell Type: heart | Dose: 22.0 mg/kg | Time: 1 d Amineptine | ID: CHEMBL418995 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1667.0 μM | Time: 16 h Amineptine | ID: CHEMBL418995 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1667.0 μM | Time: 1 d Aminoglutethimide | ID: CHEMBL488 | Study: DrugMatrix | Cell Type: liver | Dose: 350.0 mg/kg | Time: 3 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.28 μM | Time: 2 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.28 μM | Time: 8 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.28 μM | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.4 μM | Time: 2 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.4 μM | Time: 8 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.4 μM | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.0 μM | Time: 2 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.0 μM | Time: 8 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.0 μM | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.28 μM | Time: 2 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.28 μM | Time: 8 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.28 μM | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.4 μM | Time: 2 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.4 μM | Time: 8 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.4 μM | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.0 μM | Time: 2 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.0 μM | Time: 8 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.0 μM | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Amiodarone | ID: CHEMBL633 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: heart | Dose: 147.0 mg/kg | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: heart | Dose: 147.0 mg/kg | Time: 3 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: heart | Dose: 147.0 mg/kg | Time: 5 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 37.04 μM | Time: 16 h Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 37.04 μM | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: kidney | Dose: 147.0 mg/kg | Time: 1 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: kidney | Dose: 147.0 mg/kg | Time: 3 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: kidney | Dose: 147.0 mg/kg | Time: 5 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: liver | Dose: 147.0 mg/kg | Time: 3 d Amiodarone | ID: CHEMBL633 | Study: DrugMatrix | Cell Type: liver | Dose: 147.0 mg/kg | Time: 5 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 2 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 8 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Amitriptyline | ID: CHEMBL629 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Amitriptyline | ID: CHEMBL629 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 72.0 μM | Time: 16 h Amitriptyline | ID: CHEMBL629 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 72.0 μM | Time: 1 d Amitriptyline | ID: CHEMBL629 | Study: DrugMatrix | Cell Type: kidney | Dose: 160.0 mg/kg | Time: 1 d Amlodipine | ID: CHEMBL1491 | Study: DrugMatrix | Cell Type: liver | Dose: 0.2 mg/kg | Time: 6 h Amlodipine | ID: CHEMBL1491 | Study: DrugMatrix | Cell Type: liver | Dose: 0.2 mg/kg | Time: 1 d Amlodipine | ID: CHEMBL1491 | Study: DrugMatrix | Cell Type: liver | Dose: 19.0 mg/kg | Time: 3 d Ampiroxicam | ID: CHEMBL1566249 | Study: DrugMatrix | Cell Type: kidney | Dose: 94.0 mg/kg | Time: 1 d Ampiroxicam | ID: CHEMBL1566249 | Study: DrugMatrix | Cell Type: kidney | Dose: 94.0 mg/kg | Time: 3 d Ampiroxicam | ID: CHEMBL1566249 | Study: DrugMatrix | Cell Type: kidney | Dose: 94.0 mg/kg | Time: 5 d Anastrozole | ID: CHEMBL1399 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 1 d Anastrozole | ID: CHEMBL1399 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 3 d Anastrozole | ID: CHEMBL1399 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 5 d Angiotensin Ii | ID: CHEMBL216830 | Study: DrugMatrix | Cell Type: heart | Dose: 0.5 mg/kg | Time: 1 d Angiotensin Ii | ID: CHEMBL216830 | Study: DrugMatrix | Cell Type: heart | Dose: 0.5 mg/kg | Time: 3 d Angiotensin Ii | ID: CHEMBL216830 | Study: DrugMatrix | Cell Type: heart | Dose: 0.5 mg/kg | Time: 5 d Angiotensin Ii | ID: CHEMBL216830 | Study: DrugMatrix | Cell Type: heart | Dose: 0.72 mg/kg | Time: 3 d Angiotensin Ii | ID: CHEMBL216830 | Study: DrugMatrix | Cell Type: heart | Dose: 0.72 mg/kg | Time: 5 d Antimycin A | ID: CHEMBL1231114 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.03 μM | Time: 16 h Antimycin A | ID: CHEMBL1231114 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.03 μM | Time: 1 d Antipyrine | ID: CHEMBL277474 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 2 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 8 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 2 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 8 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 2 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 2 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3000.0 μM | Time: 2 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3000.0 μM | Time: 8 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3000.0 μM | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 3 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 6 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 9 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 4 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 8 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 15 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 29 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 4 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 8 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 15 d Aspirin | ID: CHEMBL25 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 29 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: heart | Dose: 35.0 mg/kg | Time: 3 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: heart | Dose: 35.0 mg/kg | Time: 5 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: kidney | Dose: 375.0 mg/kg | Time: 1 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 35.0 mg/kg | Time: 6 h Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 35.0 mg/kg | Time: 1 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 35.0 mg/kg | Time: 5 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 167.0 mg/kg | Time: 1 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 167.0 mg/kg | Time: 3 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 6 h Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 3 d Aspirin | ID: CHEMBL25 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 5 d Atenolol | ID: CHEMBL24 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 1 d Atenolol | ID: CHEMBL24 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 3 d Atenolol | ID: CHEMBL24 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 5 d Atenolol | ID: CHEMBL24 | Study: DrugMatrix | Cell Type: muscle | Dose: 1000.0 mg/kg | Time: 3 d Atenolol | ID: CHEMBL24 | Study: DrugMatrix | Cell Type: muscle | Dose: 1000.0 mg/kg | Time: 5 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 16 h Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.5 mg/kg | Time: 6 h Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.5 mg/kg | Time: 1 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: kidney | Dose: 300.0 mg/kg | Time: 1 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: kidney | Dose: 300.0 mg/kg | Time: 3 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 6 h Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 1 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 3 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 5 d Atorvastatin | ID: CHEMBL1487 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 6 h Azaribine | ID: CHEMBL515914 | Study: DrugMatrix | Cell Type: heart | Dose: 750.0 mg/kg | Time: 3 d Azaribine | ID: CHEMBL515914 | Study: DrugMatrix | Cell Type: heart | Dose: 750.0 mg/kg | Time: 5 d Azaribine | ID: CHEMBL515914 | Study: DrugMatrix | Cell Type: muscle | Dose: 750.0 mg/kg | Time: 3 d Azaribine | ID: CHEMBL515914 | Study: DrugMatrix | Cell Type: muscle | Dose: 750.0 mg/kg | Time: 5 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.14 μM | Time: 2 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.14 μM | Time: 8 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.14 μM | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.72 μM | Time: 2 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.72 μM | Time: 8 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.72 μM | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.6 μM | Time: 2 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.6 μM | Time: 8 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.6 μM | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.9 μM | Time: 2 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.9 μM | Time: 8 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.9 μM | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.6 μM | Time: 2 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.6 μM | Time: 8 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.6 μM | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 72.8 μM | Time: 2 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 72.8 μM | Time: 8 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 72.8 μM | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Azathioprine | ID: CHEMBL1542 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.5 μM | Time: 16 h Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.5 μM | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: kidney | Dose: 20.0 mg/kg | Time: 1 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: kidney | Dose: 54.0 mg/kg | Time: 3 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: kidney | Dose: 54.0 mg/kg | Time: 5 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: liver | Dose: 20.0 mg/kg | Time: 3 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 3 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 5 d Azathioprine | ID: CHEMBL1542 | Study: DrugMatrix | Cell Type: liver | Dose: 160.0 mg/kg | Time: 3 d Azithromycin | ID: CHEMBL529 | Study: DrugMatrix | Cell Type: kidney | Dose: 225.0 mg/kg | Time: 5 d Bacitracin | ID: CHEMBL1200558 | Study: DrugMatrix | Cell Type: kidney | Dose: 380.0 mg/kg | Time: 1 d Bacitracin | ID: CHEMBL1200558 | Study: DrugMatrix | Cell Type: kidney | Dose: 380.0 mg/kg | Time: 3 d Bacitracin | ID: CHEMBL1200558 | Study: DrugMatrix | Cell Type: kidney | Dose: 380.0 mg/kg | Time: 5 d Balsalazide | ID: CHEMBL102265 | Study: DrugMatrix | Cell Type: liver | Dose: 1100.0 mg/kg | Time: 6 h Balsalazide | ID: CHEMBL102265 | Study: DrugMatrix | Cell Type: liver | Dose: 1100.0 mg/kg | Time: 1 d Balsalazide | ID: CHEMBL102265 | Study: DrugMatrix | Cell Type: liver | Dose: 1100.0 mg/kg | Time: 3 d Balsalazide | ID: CHEMBL102265 | Study: DrugMatrix | Cell Type: liver | Dose: 1100.0 mg/kg | Time: 5 d Benazepril | ID: CHEMBL838 | Study: DrugMatrix | Cell Type: kidney | Dose: 1750.0 mg/kg | Time: 5 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Bendazac | ID: CHEMBL1089221 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 100.0 μM | Time: 2 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 100.0 μM | Time: 8 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 100.0 μM | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Benzbromarone | ID: CHEMBL388590 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Benzethonium Chloride | ID: CHEMBL1182210 | Study: DrugMatrix | Cell Type: heart | Dose: 138.0 mg/kg | Time: 3 d Benzethonium Chloride | ID: CHEMBL1182210 | Study: DrugMatrix | Cell Type: heart | Dose: 138.0 mg/kg | Time: 5 d Benzethonium Chloride | ID: CHEMBL1182210 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 3 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 2 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 8 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 2 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 8 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 2 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 8 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 8 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 8 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Benziodarone | ID: CHEMBL232201 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Beta-Naphthoflavone | ID: CHEMBL26260 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 1 d Beta-Naphthoflavone | ID: CHEMBL26260 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 3 d Beta-Naphthoflavone | ID: CHEMBL26260 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 5 d Betamethasone | ID: CHEMBL1200376 | Study: DrugMatrix | Cell Type: liver | Dose: 79.0 mg/kg | Time: 1 d Betamethasone | ID: CHEMBL1200376 | Study: DrugMatrix | Cell Type: liver | Dose: 79.0 mg/kg | Time: 3 d Betamethasone | ID: CHEMBL1200376 | Study: DrugMatrix | Cell Type: liver | Dose: 79.0 mg/kg | Time: 5 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: heart | Dose: 617.0 mg/kg | Time: 1 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: heart | Dose: 617.0 mg/kg | Time: 7 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 6 h Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 1 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 3 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 5 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 6 h Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 1 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 3 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 7 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 617.0 mg/kg | Time: 6 h Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 617.0 mg/kg | Time: 1 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 617.0 mg/kg | Time: 3 d Bezafibrate | ID: CHEMBL264374 | Study: DrugMatrix | Cell Type: liver | Dose: 617.0 mg/kg | Time: 7 d Bis(2-Ethylhexyl) Phthalate | ID: CHEMBL402794 | Study: DrugMatrix | Cell Type: liver | Dose: 1000.0 mg/kg | Time: 3 d Bis(2-Ethylhexyl) Phthalate | ID: CHEMBL402794 | Study: DrugMatrix | Cell Type: liver | Dose: 1000.0 mg/kg | Time: 5 d Bisphenol A | ID: CHEMBL418971 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 6 h Bisphenol A | ID: CHEMBL418971 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 1 d Bisphenol A | ID: CHEMBL418971 | Study: DrugMatrix | Cell Type: kidney | Dose: 610.0 mg/kg | Time: 1 d Bisphenol A | ID: CHEMBL418971 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 1 d Bisphenol A | ID: CHEMBL418971 | Study: DrugMatrix | Cell Type: liver | Dose: 610.0 mg/kg | Time: 6 h Bisphenol A | ID: CHEMBL418971 | Study: DrugMatrix | Cell Type: liver | Dose: 610.0 mg/kg | Time: 1 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: kidney | Dose: 59.0 mg/kg | Time: 6 h Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: kidney | Dose: 59.0 mg/kg | Time: 1 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: kidney | Dose: 333.0 mg/kg | Time: 1 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: kidney | Dose: 333.0 mg/kg | Time: 3 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: liver | Dose: 59.0 mg/kg | Time: 6 h Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: liver | Dose: 59.0 mg/kg | Time: 1 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: liver | Dose: 59.0 mg/kg | Time: 3 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: liver | Dose: 59.0 mg/kg | Time: 5 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: liver | Dose: 333.0 mg/kg | Time: 6 h Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: liver | Dose: 333.0 mg/kg | Time: 1 d Bithionol | ID: CHEMBL290106 | Study: DrugMatrix | Cell Type: liver | Dose: 333.0 mg/kg | Time: 5 d Bromfenac | ID: CHEMBL1077 | Study: DrugMatrix | Cell Type: kidney | Dose: 5.0 mg/kg | Time: 1 d Bromfenac | ID: CHEMBL1077 | Study: DrugMatrix | Cell Type: kidney | Dose: 5.0 mg/kg | Time: 3 d Bromfenac | ID: CHEMBL1077 | Study: DrugMatrix | Cell Type: kidney | Dose: 5.0 mg/kg | Time: 5 d Bromisovalum | ID: CHEMBL1515611 | Study: DrugMatrix | Cell Type: kidney | Dose: 250.0 mg/kg | Time: 1 d Bromisovalum | ID: CHEMBL1515611 | Study: DrugMatrix | Cell Type: kidney | Dose: 250.0 mg/kg | Time: 5 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 2 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 8 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 2 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 8 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 2 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 8 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Bromobenzene | ID: CHEMBL16068 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Bromobenzene | ID: CHEMBL16068 | Study: DrugMatrix | Cell Type: kidney | Dose: 439.0 mg/kg | Time: 1 d Bromobenzene | ID: CHEMBL16068 | Study: DrugMatrix | Cell Type: kidney | Dose: 439.0 mg/kg | Time: 3 d Bromodichloromethane | ID: CHEMBL346231 | Study: DrugMatrix | Cell Type: kidney | Dose: 430.0 mg/kg | Time: 3 d Bromodichloromethane | ID: CHEMBL346231 | Study: DrugMatrix | Cell Type: kidney | Dose: 430.0 mg/kg | Time: 5 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 2 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 8 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 2 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 8 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 3 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 6 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 9 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 4 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 8 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 15 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 29 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 3 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 6 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 9 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 3 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 6 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 9 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 3 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 6 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 9 h Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 1 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 4 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 8 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 15 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 29 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Bromoethylamine | ID: CHEMBL1697693 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 3 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 6 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 9 h Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 1 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Bucetin | ID: CHEMBL1697856 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Buspirone | ID: CHEMBL49 | Study: DrugMatrix | Cell Type: heart | Dose: 196.0 mg/kg | Time: 3 d Buspirone | ID: CHEMBL49 | Study: DrugMatrix | Cell Type: heart | Dose: 196.0 mg/kg | Time: 5 d Buspirone | ID: CHEMBL49 | Study: DrugMatrix | Cell Type: muscle | Dose: 196.0 mg/kg | Time: 3 d Buspirone | ID: CHEMBL49 | Study: DrugMatrix | Cell Type: muscle | Dose: 196.0 mg/kg | Time: 5 d Busulfan | ID: CHEMBL820 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 1 d Busulfan | ID: CHEMBL820 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Busulfan | ID: CHEMBL820 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 16 h Busulfan | ID: CHEMBL820 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 1 d Buthionine Sulfoximine | ID: CHEMBL1609891 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 100000.0 μM | Time: 16 h Buthionine Sulfoximine | ID: CHEMBL1609891 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 100000.0 μM | Time: 1 d Cadmium Dichloride | ID: CHEMBL1458880 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 8.0 μM | Time: 16 h Cadmium Dichloride | ID: CHEMBL1458880 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 8.0 μM | Time: 1 d Cadmium Dichloride | ID: CHEMBL1458880 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.0 mg/kg | Time: 5 d Cadmium Dichloride | ID: CHEMBL1458880 | Study: DrugMatrix | Cell Type: kidney | Dose: 66.0 mg/kg | Time: 1 d Cadmium Dichloride | ID: CHEMBL1458880 | Study: DrugMatrix | Cell Type: kidney | Dose: 66.0 mg/kg | Time: 5 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1500.0 μM | Time: 8 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1500.0 μM | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7500.0 μM | Time: 8 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7500.0 μM | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Caffeine | ID: CHEMBL113 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Calciol | ID: CHEMBL846 | Study: DrugMatrix | Cell Type: kidney | Dose: 0.04 mg/kg | Time: 1 d Calciol | ID: CHEMBL846 | Study: DrugMatrix | Cell Type: kidney | Dose: 0.04 mg/kg | Time: 3 d Calciol | ID: CHEMBL846 | Study: DrugMatrix | Cell Type: kidney | Dose: 0.04 mg/kg | Time: 5 d Calciol | ID: CHEMBL1042 | Study: DrugMatrix | Cell Type: kidney | Dose: 8.0 mg/kg | Time: 3 d Calciol | ID: CHEMBL1042 | Study: DrugMatrix | Cell Type: kidney | Dose: 8.0 mg/kg | Time: 5 d Calciol | ID: CHEMBL846 | Study: DrugMatrix | Cell Type: liver | Dose: 8.0 mg/kg | Time: 3 d Candesartan | ID: CHEMBL1016 | Study: DrugMatrix | Cell Type: heart | Dose: 1300.0 mg/kg | Time: 1 d Candesartan | ID: CHEMBL1016 | Study: DrugMatrix | Cell Type: heart | Dose: 1300.0 mg/kg | Time: 3 d Candesartan | ID: CHEMBL1016 | Study: DrugMatrix | Cell Type: heart | Dose: 1300.0 mg/kg | Time: 5 d Candesartan | ID: CHEMBL1016 | Study: DrugMatrix | Cell Type: kidney | Dose: 1300.0 mg/kg | Time: 3 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1600.0 μM | Time: 8 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1600.0 μM | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8000.0 μM | Time: 8 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8000.0 μM | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Captopril | ID: CHEMBL1560 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Captopril | ID: CHEMBL1560 | Study: DrugMatrix | Cell Type: kidney | Dose: 1750.0 mg/kg | Time: 6 h Captopril | ID: CHEMBL1560 | Study: DrugMatrix | Cell Type: kidney | Dose: 1750.0 mg/kg | Time: 5 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 2 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 8 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 2 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 2 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Carbamazepine | ID: CHEMBL108 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Carbamazepine | ID: CHEMBL108 | Study: DrugMatrix | Cell Type: liver | Dose: 490.0 mg/kg | Time: 1 d Carbamazepine | ID: CHEMBL108 | Study: DrugMatrix | Cell Type: liver | Dose: 490.0 mg/kg | Time: 3 d Carbamazepine | ID: CHEMBL108 | Study: DrugMatrix | Cell Type: liver | Dose: 490.0 mg/kg | Time: 5 d Carbimazole | ID: CHEMBL508102 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 1 d Carbimazole | ID: CHEMBL508102 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 3 d Carbimazole | ID: CHEMBL508102 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 5 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 2 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 8 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 2 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 8 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Carboplatin | ID: CHEMBL288376 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Carboplatin | ID: CHEMBL1351 | Study: DrugMatrix | Cell Type: kidney | Dose: 5.0 mg/kg | Time: 5 d Carboplatin | ID: CHEMBL1351 | Study: DrugMatrix | Cell Type: kidney | Dose: 14.0 mg/kg | Time: 1 d Carboplatin | ID: CHEMBL1351 | Study: DrugMatrix | Cell Type: kidney | Dose: 14.0 mg/kg | Time: 3 d Carboplatin | ID: CHEMBL1351 | Study: DrugMatrix | Cell Type: kidney | Dose: 14.0 mg/kg | Time: 5 d Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 550.0 μM | Time: 16 h Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 550.0 μM | Time: 1 d Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 4.0 mg/kg | Time: 6 h Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 4.0 mg/kg | Time: 1 d Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 4.0 mg/kg | Time: 3 d Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 4.0 mg/kg | Time: 5 d Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 6 h Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 1 d Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 3 d Carmustine | ID: CHEMBL513 | Study: DrugMatrix | Cell Type: liver | Dose: 16.0 mg/kg | Time: 5 d Carvedilol | ID: CHEMBL723 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 50.0 μM | Time: 16 h Carvedilol | ID: CHEMBL723 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 50.0 μM | Time: 1 d Carvedilol | ID: CHEMBL723 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 1 d Carvedilol | ID: CHEMBL723 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d Carvedilol | ID: CHEMBL723 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 5 d Catechol | ID: CHEMBL280998 | Study: DrugMatrix | Cell Type: kidney | Dose: 40.0 mg/kg | Time: 6 h Catechol | ID: CHEMBL280998 | Study: DrugMatrix | Cell Type: kidney | Dose: 40.0 mg/kg | Time: 1 d Catechol | ID: CHEMBL280998 | Study: DrugMatrix | Cell Type: kidney | Dose: 195.0 mg/kg | Time: 3 d Catechol | ID: CHEMBL679 | Study: DrugMatrix | Cell Type: liver | Dose: 40.0 mg/kg | Time: 6 h Catechol | ID: CHEMBL679 | Study: DrugMatrix | Cell Type: liver | Dose: 40.0 mg/kg | Time: 1 d Catechol | ID: CHEMBL679 | Study: DrugMatrix | Cell Type: liver | Dose: 195.0 mg/kg | Time: 6 h Catechol | ID: CHEMBL679 | Study: DrugMatrix | Cell Type: liver | Dose: 195.0 mg/kg | Time: 1 d Catechol | ID: CHEMBL679 | Study: DrugMatrix | Cell Type: liver | Dose: 195.0 mg/kg | Time: 3 d Catechol | ID: CHEMBL679 | Study: DrugMatrix | Cell Type: liver | Dose: 195.0 mg/kg | Time: 5 d Celecoxib | ID: CHEMBL118 | Study: DrugMatrix | Cell Type: heart | Dose: 35.0 mg/kg | Time: 5 d Celecoxib | ID: CHEMBL118 | Study: DrugMatrix | Cell Type: heart | Dose: 400.0 mg/kg | Time: 3 d Celecoxib | ID: CHEMBL118 | Study: DrugMatrix | Cell Type: heart | Dose: 400.0 mg/kg | Time: 5 d Celecoxib | ID: CHEMBL118 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 100.0 μM | Time: 16 h Celecoxib | ID: CHEMBL118 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 100.0 μM | Time: 1 d Cephalexin | ID: CHEMBL1727 | Study: DrugMatrix | Cell Type: kidney | Dose: 2500.0 mg/kg | Time: 3 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 2 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 8 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 2 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 8 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2000.0 mg/kg | Time: 4 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2000.0 mg/kg | Time: 8 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2000.0 mg/kg | Time: 15 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2000.0 mg/kg | Time: 29 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 3 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 6 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 9 h Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 1 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2000.0 mg/kg | Time: 4 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2000.0 mg/kg | Time: 8 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2000.0 mg/kg | Time: 15 d Cephalothin | ID: CHEMBL617 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2000.0 mg/kg | Time: 29 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 16 h Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: kidney | Dose: 7.0 mg/kg | Time: 1 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: kidney | Dose: 7.0 mg/kg | Time: 3 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: kidney | Dose: 7.0 mg/kg | Time: 5 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: liver | Dose: 0.05 mg/kg | Time: 6 h Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: liver | Dose: 0.05 mg/kg | Time: 1 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: liver | Dose: 7.0 mg/kg | Time: 1 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: liver | Dose: 7.0 mg/kg | Time: 3 d Cerivastatin | ID: CHEMBL1477 | Study: DrugMatrix | Cell Type: liver | Dose: 7.0 mg/kg | Time: 5 d Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: heart | Dose: 4.5 mg/kg | Time: 3 d Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: heart | Dose: 4.5 mg/kg | Time: 5 d Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1540.0 μM | Time: 16 h Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1540.0 μM | Time: 1 d Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: liver | Dose: 0.6 mg/kg | Time: 6 h Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: liver | Dose: 0.6 mg/kg | Time: 5 d Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: liver | Dose: 4.5 mg/kg | Time: 3 d Chlorambucil | ID: CHEMBL515 | Study: DrugMatrix | Cell Type: liver | Dose: 4.5 mg/kg | Time: 5 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 18.0 μM | Time: 2 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 18.0 μM | Time: 8 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 18.0 μM | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 90.0 μM | Time: 2 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 90.0 μM | Time: 8 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 90.0 μM | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 450.0 μM | Time: 2 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 450.0 μM | Time: 8 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 450.0 μM | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 90.0 μM | Time: 8 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 90.0 μM | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 450.0 μM | Time: 8 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 450.0 μM | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Chloramphenicol | ID: CHEMBL130 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 2 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 8 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 8 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 8 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Chlormadinone | ID: CHEMBL1697830 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 2 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 8 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 2 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 8 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 250.0 μM | Time: 8 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 250.0 μM | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 3 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 6 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 9 h Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 1 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 4 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 8 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 15 d Chlormezanone | ID: CHEMBL1200714 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 29 d Chlorobenzene | ID: CHEMBL16200 | Study: DrugMatrix | Cell Type: heart | Dose: 500.0 mg/kg | Time: 1 d Chlorobenzene | ID: CHEMBL16200 | Study: DrugMatrix | Cell Type: heart | Dose: 500.0 mg/kg | Time: 3 d Chlorobenzene | ID: CHEMBL16200 | Study: DrugMatrix | Cell Type: heart | Dose: 500.0 mg/kg | Time: 5 d Chlorobenzene | ID: CHEMBL16200 | Study: DrugMatrix | Cell Type: kidney | Dose: 500.0 mg/kg | Time: 1 d Chlorobenzene | ID: CHEMBL16200 | Study: DrugMatrix | Cell Type: kidney | Dose: 500.0 mg/kg | Time: 3 d Chlorobenzene | ID: CHEMBL16200 | Study: DrugMatrix | Cell Type: kidney | Dose: 500.0 mg/kg | Time: 5 d Chloroform | ID: CHEMBL44618 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 6 h Chloroform | ID: CHEMBL44618 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 1 d Chloroform | ID: CHEMBL44618 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 3 d Chloroform | ID: CHEMBL44618 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 5 d Chloroquine | ID: CHEMBL1656 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 21.95 μM | Time: 16 h Chloroquine | ID: CHEMBL1656 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 21.95 μM | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 18.0 μM | Time: 8 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 18.0 μM | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 90.0 μM | Time: 8 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 90.0 μM | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Chlorpheniramine | ID: CHEMBL505 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.8 μM | Time: 2 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.8 μM | Time: 8 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.8 μM | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 2 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 8 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 2 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 8 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 2 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 8 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 3 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 6 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 9 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 4 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 8 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 15 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 29 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 4 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 8 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 15 d Chlorpromazine | ID: CHEMBL71 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 29 d Chlorpromazine | ID: CHEMBL71 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 43.9 μM | Time: 16 h Chlorpromazine | ID: CHEMBL71 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 43.9 μM | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 2 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 8 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 2 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 8 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 750.0 μM | Time: 2 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 750.0 μM | Time: 8 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 750.0 μM | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 8 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 750.0 μM | Time: 8 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 750.0 μM | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Chlorpropamide | ID: CHEMBL498 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Chlorpropamide | ID: CHEMBL498 | Study: DrugMatrix | Cell Type: heart | Dose: 269.0 mg/kg | Time: 1 d Chlorpropamide | ID: CHEMBL498 | Study: DrugMatrix | Cell Type: heart | Dose: 269.0 mg/kg | Time: 3 d Chlorpropamide | ID: CHEMBL498 | Study: DrugMatrix | Cell Type: heart | Dose: 269.0 mg/kg | Time: 5 d Chlorpropamide | ID: CHEMBL498 | Study: DrugMatrix | Cell Type: muscle | Dose: 269.0 mg/kg | Time: 3 d Chlorpropamide | ID: CHEMBL498 | Study: DrugMatrix | Cell Type: muscle | Dose: 269.0 mg/kg | Time: 5 d Chlorpyrifos | ID: CHEMBL463210 | Study: DrugMatrix | Cell Type: heart | Dose: 82.0 mg/kg | Time: 5 d Cilostazol | ID: CHEMBL799 | Study: DrugMatrix | Cell Type: heart | Dose: 1500.0 mg/kg | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 2 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 8 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 2 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 2 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Cimetidine | ID: CHEMBL30 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Cinnarizine | ID: CHEMBL43064 | Study: DrugMatrix | Cell Type: liver | Dose: 750.0 mg/kg | Time: 3 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 2 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 8 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 2 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 8 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 2 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 8 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 8 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 8 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Ciprofloxacin | ID: CHEMBL8 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Cisapride | ID: CHEMBL1729 | Study: DrugMatrix | Cell Type: heart | Dose: 250.0 mg/kg | Time: 3 d Cisapride | ID: CHEMBL1729 | Study: DrugMatrix | Cell Type: heart | Dose: 250.0 mg/kg | Time: 5 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.3 mg/kg | Time: 3 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.3 mg/kg | Time: 6 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.3 mg/kg | Time: 9 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.3 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 3 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 6 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 9 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 4 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 8 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 15 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 29 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 4 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 8 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 15 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 29 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.3 mg/kg | Time: 3 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.3 mg/kg | Time: 6 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.3 mg/kg | Time: 9 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.3 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 3 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 6 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 9 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 3 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 6 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 9 h Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 4 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 8 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 15 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 29 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 4 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 8 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 15 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 29 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Cisplatin | ID: CHEMBL2068237 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 63.0 μM | Time: 16 h Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 63.0 μM | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 0.5 mg/kg | Time: 5 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.17 mg/kg | Time: 6 h Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.17 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.17 mg/kg | Time: 3 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.17 mg/kg | Time: 5 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.0 mg/kg | Time: 1 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.0 mg/kg | Time: 3 d Cisplatin | ID: CHEMBL2068237 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.0 mg/kg | Time: 5 d Citalopram | ID: CHEMBL399730 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 150.0 μM | Time: 16 h Citalopram | ID: CHEMBL399730 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 150.0 μM | Time: 1 d Citalopram | ID: CHEMBL399730 | Study: DrugMatrix | Cell Type: liver | Dose: 90.0 mg/kg | Time: 6 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 2 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 8 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 2 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 2 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Clofibrate | ID: CHEMBL565 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: heart | Dose: 448.0 mg/kg | Time: 1 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: heart | Dose: 448.0 mg/kg | Time: 3 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: heart | Dose: 448.0 mg/kg | Time: 5 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 1 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 16 h Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 1 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: kidney | Dose: 130.0 mg/kg | Time: 6 h Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: kidney | Dose: 130.0 mg/kg | Time: 1 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: kidney | Dose: 500.0 mg/kg | Time: 3 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: liver | Dose: 130.0 mg/kg | Time: 3 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: liver | Dose: 130.0 mg/kg | Time: 7 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: liver | Dose: 448.0 mg/kg | Time: 1 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: liver | Dose: 448.0 mg/kg | Time: 3 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: liver | Dose: 448.0 mg/kg | Time: 5 d Clofibric Acid | ID: CHEMBL683 | Study: DrugMatrix | Cell Type: liver | Dose: 500.0 mg/kg | Time: 7 d Clomiphene | ID: CHEMBL954 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 3 d Clomiphene | ID: CHEMBL954 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 5 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 2 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 8 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.0 μM | Time: 8 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.0 μM | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Clomipramine | ID: CHEMBL415 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Clomipramine | ID: CHEMBL415 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 50.0 μM | Time: 16 h Clomipramine | ID: CHEMBL415 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 50.0 μM | Time: 1 d Clomipramine | ID: CHEMBL415 | Study: DrugMatrix | Cell Type: liver | Dose: 115.0 mg/kg | Time: 3 d Clonazepam | ID: CHEMBL452 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 6 h Clonazepam | ID: CHEMBL452 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 1 d Clonazepam | ID: CHEMBL452 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 3 d Clonazepam | ID: CHEMBL452 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 5 d Closantel | ID: CHEMBL12131 | Study: DrugMatrix | Cell Type: liver | Dose: 22.0 mg/kg | Time: 1 d Closantel | ID: CHEMBL12131 | Study: DrugMatrix | Cell Type: liver | Dose: 22.0 mg/kg | Time: 3 d Closantel | ID: CHEMBL12131 | Study: DrugMatrix | Cell Type: liver | Dose: 22.0 mg/kg | Time: 5 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 60.0 μM | Time: 16 h Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 60.0 μM | Time: 1 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 52.0 mg/kg | Time: 6 h Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 52.0 mg/kg | Time: 1 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 52.0 mg/kg | Time: 3 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 52.0 mg/kg | Time: 5 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 89.0 mg/kg | Time: 6 h Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 89.0 mg/kg | Time: 1 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 89.0 mg/kg | Time: 3 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 89.0 mg/kg | Time: 5 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 178.0 mg/kg | Time: 6 h Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 178.0 mg/kg | Time: 3 d Clotrimazole | ID: CHEMBL104 | Study: DrugMatrix | Cell Type: liver | Dose: 178.0 mg/kg | Time: 5 d Clozapine | ID: CHEMBL42 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 69.0 μM | Time: 16 h Clozapine | ID: CHEMBL42 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 69.0 μM | Time: 1 d Cobalt Dichloride | ID: CHEMBL1909055 | Study: DrugMatrix | Cell Type: heart | Dose: 10.0 mg/kg | Time: 5 d Cobalt Dichloride | ID: CHEMBL1909055 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 5 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 2 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 8 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5000.0 μM | Time: 2 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5000.0 μM | Time: 8 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5000.0 μM | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 8 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 8 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.5 mg/kg | Time: 3 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.5 mg/kg | Time: 6 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.5 mg/kg | Time: 9 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.5 mg/kg | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 3 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 6 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 9 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 4 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 8 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 15 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 29 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 4 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 8 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 15 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 29 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 4 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 8 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 15 d Colchicine | ID: CHEMBL107 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 29 d Colchicine | ID: CHEMBL107 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 16 h Colchicine | ID: CHEMBL107 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 1 d Colchicine | ID: CHEMBL107 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2000.0 μM | Time: 16 h Colchicine | ID: CHEMBL107 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2000.0 μM | Time: 1 d Coralgil | ID: CHEMBL1615358 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 20.0 μM | Time: 16 h Coralgil | ID: CHEMBL1615358 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 20.0 μM | Time: 1 d Cortisone | ID: CHEMBL111861 | Study: DrugMatrix | Cell Type: heart | Dose: 206.0 mg/kg | Time: 1 d Cortisone | ID: CHEMBL111861 | Study: DrugMatrix | Cell Type: kidney | Dose: 206.0 mg/kg | Time: 1 d Cortisone | ID: CHEMBL111861 | Study: DrugMatrix | Cell Type: kidney | Dose: 206.0 mg/kg | Time: 3 d Cortisone | ID: CHEMBL111861 | Study: DrugMatrix | Cell Type: kidney | Dose: 206.0 mg/kg | Time: 5 d Cortisone | ID: CHEMBL111861 | Study: DrugMatrix | Cell Type: liver | Dose: 206.0 mg/kg | Time: 1 d Cortisone | ID: CHEMBL111861 | Study: DrugMatrix | Cell Type: liver | Dose: 206.0 mg/kg | Time: 3 d Cortisone | ID: CHEMBL111861 | Study: DrugMatrix | Cell Type: liver | Dose: 206.0 mg/kg | Time: 5 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 2 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 8 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 2 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 2 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Coumarin | ID: CHEMBL6466 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Cromoglycic Acid | ID: CHEMBL428880 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Crotamiton | ID: CHEMBL1200709 | Study: DrugMatrix | Cell Type: liver | Dose: 750.0 mg/kg | Time: 1 d Crotamiton | ID: CHEMBL1200709 | Study: DrugMatrix | Cell Type: liver | Dose: 750.0 mg/kg | Time: 3 d Crotamiton | ID: CHEMBL1200709 | Study: DrugMatrix | Cell Type: liver | Dose: 750.0 mg/kg | Time: 5 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 2 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 8 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 2 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 2 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 4 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 8 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 15 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.5 mg/kg | Time: 29 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 4 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 8 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 15 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 29 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.5 mg/kg | Time: 3 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.5 mg/kg | Time: 6 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.5 mg/kg | Time: 9 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.5 mg/kg | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 3 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 6 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 9 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 3 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 6 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 9 h Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 1 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.5 mg/kg | Time: 4 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.5 mg/kg | Time: 8 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.5 mg/kg | Time: 15 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.5 mg/kg | Time: 29 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 5.0 mg/kg | Time: 4 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 5.0 mg/kg | Time: 8 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 5.0 mg/kg | Time: 15 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 5.0 mg/kg | Time: 29 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Cyclophosphamide | ID: CHEMBL88 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Cyclophosphamide | ID: CHEMBL88 | Study: DrugMatrix | Cell Type: heart | Dose: 25.0 mg/kg | Time: 3 d Cyclophosphamide | ID: CHEMBL88 | Study: DrugMatrix | Cell Type: heart | Dose: 25.0 mg/kg | Time: 5 d Cyclophosphamide | ID: CHEMBL88 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1320.0 μM | Time: 16 h Cyclophosphamide | ID: CHEMBL88 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1320.0 μM | Time: 1 d Cyclopropane Carboxylic Acid | ID: CHEMBL265325 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 1 d Cyclopropane Carboxylic Acid | ID: CHEMBL265325 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 3 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: heart | Dose: 300.0 mg/kg | Time: 1 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: heart | Dose: 300.0 mg/kg | Time: 3 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: heart | Dose: 300.0 mg/kg | Time: 5 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: heart | Dose: 350.0 mg/kg | Time: 3 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: heart | Dose: 350.0 mg/kg | Time: 5 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 10.0 μM | Time: 16 h Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 10.0 μM | Time: 1 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: kidney | Dose: 70.0 mg/kg | Time: 3 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: kidney | Dose: 70.0 mg/kg | Time: 5 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: kidney | Dose: 350.0 mg/kg | Time: 3 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: kidney | Dose: 350.0 mg/kg | Time: 5 d Cyclosporin A | ID: CHEMBL442519 | Study: DrugMatrix | Cell Type: liver | Dose: 350.0 mg/kg | Time: 5 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.24 μM | Time: 2 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.24 μM | Time: 8 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.24 μM | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 2 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 8 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 2 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 8 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Cyclosporine A | ID: CHEMBL160 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Cyproheptadine | ID: CHEMBL516 | Study: DrugMatrix | Cell Type: heart | Dose: 37.0 mg/kg | Time: 1 d Cyproheptadine | ID: CHEMBL516 | Study: DrugMatrix | Cell Type: heart | Dose: 37.0 mg/kg | Time: 3 d Cyproheptadine | ID: CHEMBL516 | Study: DrugMatrix | Cell Type: heart | Dose: 37.0 mg/kg | Time: 5 d Cyproterone Acetate | ID: CHEMBL139835 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 6 h Cyproterone Acetate | ID: CHEMBL139835 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 1 d Cyproterone Acetate | ID: CHEMBL139835 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 3 d Cyproterone Acetate | ID: CHEMBL139835 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 5 d Cytarabine | ID: CHEMBL2092816 | Study: DrugMatrix | Cell Type: kidney | Dose: 487.0 mg/kg | Time: 5 d Cytarabine | ID: CHEMBL803 | Study: DrugMatrix | Cell Type: liver | Dose: 487.0 mg/kg | Time: 3 d Cytochalasin B | ID: CHEMBL411729 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 167.0 μM | Time: 16 h Cytochalasin B | ID: CHEMBL411729 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 167.0 μM | Time: 1 d D-Galactosamine | ID: CHEMBL606759 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 470.0 μM | Time: 16 h D-Galactosamine | ID: CHEMBL606759 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 470.0 μM | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.4 μM | Time: 2 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.4 μM | Time: 8 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.4 μM | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.0 μM | Time: 2 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.0 μM | Time: 8 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.0 μM | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 35.0 μM | Time: 2 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 35.0 μM | Time: 8 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 35.0 μM | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.0 μM | Time: 8 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.0 μM | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 35.0 μM | Time: 8 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 35.0 μM | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Danazol | ID: CHEMBL1479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Danazol | ID: CHEMBL1479 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 95.0 μM | Time: 16 h Danazol | ID: CHEMBL1479 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 95.0 μM | Time: 1 d Danazol | ID: CHEMBL1479 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 2 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 8 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.0 μM | Time: 8 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.0 μM | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 3 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 6 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 9 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 3 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 6 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 9 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 3 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 6 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 9 h Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 1 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 4 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 8 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 15 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 29 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 4 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 8 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 15 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 29 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 4 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 8 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 15 d Dantrolene | ID: CHEMBL1201288 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 29 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 1 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 3 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 5 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: heart | Dose: 3.25 mg/kg | Time: 1 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: heart | Dose: 3.25 mg/kg | Time: 3 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: heart | Dose: 3.25 mg/kg | Time: 5 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.5 μM | Time: 16 h Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.5 μM | Time: 1 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: kidney | Dose: 3.25 mg/kg | Time: 3 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: kidney | Dose: 3.25 mg/kg | Time: 5 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: liver | Dose: 3.25 mg/kg | Time: 1 d Daunorubicin | ID: CHEMBL178 | Study: DrugMatrix | Cell Type: liver | Dose: 3.25 mg/kg | Time: 3 d Desloratadine | ID: CHEMBL998 | Study: DrugMatrix | Cell Type: heart | Dose: 2000.0 mg/kg | Time: 1 d Desloratadine | ID: CHEMBL998 | Study: DrugMatrix | Cell Type: heart | Dose: 2000.0 mg/kg | Time: 5 d Desloratadine | ID: CHEMBL1172 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 57.0 μM | Time: 16 h Desloratadine | ID: CHEMBL1172 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 57.0 μM | Time: 1 d Desloratadine | ID: CHEMBL998 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 62.25 μM | Time: 16 h Desloratadine | ID: CHEMBL998 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 62.25 μM | Time: 1 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: heart | Dose: 1.0 mg/kg | Time: 3 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: heart | Dose: 1.0 mg/kg | Time: 5 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 456.0 μM | Time: 16 h Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 456.0 μM | Time: 1 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: kidney | Dose: 300.0 mg/kg | Time: 1 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: kidney | Dose: 300.0 mg/kg | Time: 3 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: liver | Dose: 1.0 mg/kg | Time: 6 h Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: liver | Dose: 1.0 mg/kg | Time: 1 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: liver | Dose: 1.0 mg/kg | Time: 3 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: liver | Dose: 1.0 mg/kg | Time: 5 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 6 h Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 1 d Dexamethasone | ID: CHEMBL384467 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 3 d Dexchlorpheniramine | ID: CHEMBL1201353 | Study: DrugMatrix | Cell Type: heart | Dose: 47.0 mg/kg | Time: 3 d Dexchlorpheniramine | ID: CHEMBL1201353 | Study: DrugMatrix | Cell Type: heart | Dose: 47.0 mg/kg | Time: 5 d Dexchlorpheniramine | ID: CHEMBL1201353 | Study: DrugMatrix | Cell Type: muscle | Dose: 47.0 mg/kg | Time: 3 d Dexchlorpheniramine | ID: CHEMBL1201353 | Study: DrugMatrix | Cell Type: muscle | Dose: 47.0 mg/kg | Time: 5 d Dexibuprofen | ID: CHEMBL175 | Study: DrugMatrix | Cell Type: kidney | Dose: 239.0 mg/kg | Time: 1 d Dexibuprofen | ID: CHEMBL175 | Study: DrugMatrix | Cell Type: kidney | Dose: 239.0 mg/kg | Time: 3 d Dexibuprofen | ID: CHEMBL175 | Study: DrugMatrix | Cell Type: kidney | Dose: 239.0 mg/kg | Time: 5 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 2 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 8 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 2 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 8 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 125.0 μM | Time: 2 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 125.0 μM | Time: 8 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 125.0 μM | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 2 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 2 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 250.0 μM | Time: 2 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 250.0 μM | Time: 8 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 250.0 μM | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 3 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 6 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 9 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 3 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 6 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 9 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 3 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 6 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 9 h Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 1 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 4 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 8 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 15 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 29 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 4 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 8 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 15 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 29 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 4 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 8 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 15 d Diazepam | ID: CHEMBL12 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 29 d Diazepam | ID: CHEMBL12 | Study: DrugMatrix | Cell Type: liver | Dose: 710.0 mg/kg | Time: 1 d Diazepam | ID: CHEMBL12 | Study: DrugMatrix | Cell Type: liver | Dose: 710.0 mg/kg | Time: 3 d Diazepam | ID: CHEMBL12 | Study: DrugMatrix | Cell Type: liver | Dose: 710.0 mg/kg | Time: 5 d Dibenzothiazol-2-Yl Disulfide | ID: CHEMBL508112 | Study: DrugMatrix | Cell Type: kidney | Dose: 2600.0 mg/kg | Time: 1 d Dibenzothiazol-2-Yl Disulfide | ID: CHEMBL508112 | Study: DrugMatrix | Cell Type: kidney | Dose: 2600.0 mg/kg | Time: 3 d Dibenzothiazol-2-Yl Disulfide | ID: CHEMBL508112 | Study: DrugMatrix | Cell Type: kidney | Dose: 2600.0 mg/kg | Time: 5 d Dibenzothiazol-2-Yl Disulfide | ID: CHEMBL508112 | Study: DrugMatrix | Cell Type: liver | Dose: 2600.0 mg/kg | Time: 1 d Dibenzothiazol-2-Yl Disulfide | ID: CHEMBL508112 | Study: DrugMatrix | Cell Type: liver | Dose: 2600.0 mg/kg | Time: 3 d Dibenzothiazol-2-Yl Disulfide | ID: CHEMBL508112 | Study: DrugMatrix | Cell Type: liver | Dose: 2600.0 mg/kg | Time: 5 d Dibromochloromethane | ID: CHEMBL157093 | Study: DrugMatrix | Cell Type: kidney | Dose: 325.0 mg/kg | Time: 3 d Dibromochloromethane | ID: CHEMBL157093 | Study: DrugMatrix | Cell Type: kidney | Dose: 325.0 mg/kg | Time: 5 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 2 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 8 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 2 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 8 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 2 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 8 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 2 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Diclofenac | ID: CHEMBL139 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Diclofenac | ID: CHEMBL1033 | Study: DrugMatrix | Cell Type: kidney | Dose: 3.5 mg/kg | Time: 5 d Diclofenac | ID: CHEMBL1033 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 6 h Diclofenac | ID: CHEMBL139 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 1 d Diclofenac | ID: CHEMBL139 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 3 d Dicyclomine | ID: CHEMBL1123 | Study: DrugMatrix | Cell Type: heart | Dose: 645.0 mg/kg | Time: 1 d Dicyclomine | ID: CHEMBL1123 | Study: DrugMatrix | Cell Type: heart | Dose: 645.0 mg/kg | Time: 3 d Dicyclomine | ID: CHEMBL1123 | Study: DrugMatrix | Cell Type: heart | Dose: 645.0 mg/kg | Time: 5 d Dicyclomine | ID: CHEMBL1123 | Study: DrugMatrix | Cell Type: muscle | Dose: 645.0 mg/kg | Time: 3 d Dicyclomine | ID: CHEMBL1123 | Study: DrugMatrix | Cell Type: muscle | Dose: 645.0 mg/kg | Time: 5 d Didanosine | ID: CHEMBL1460 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 16 h Didanosine | ID: CHEMBL1460 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 1 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 120.0 μM | Time: 16 h Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 120.0 μM | Time: 1 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.8 mg/kg | Time: 6 h Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.8 mg/kg | Time: 3 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: kidney | Dose: 280.0 mg/kg | Time: 3 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: kidney | Dose: 280.0 mg/kg | Time: 5 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: liver | Dose: 2.8 mg/kg | Time: 6 h Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: liver | Dose: 2.8 mg/kg | Time: 1 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: liver | Dose: 2.8 mg/kg | Time: 3 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: liver | Dose: 2.8 mg/kg | Time: 5 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: liver | Dose: 280.0 mg/kg | Time: 6 h Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: liver | Dose: 280.0 mg/kg | Time: 3 d Diethylstilbestrol | ID: CHEMBL411 | Study: DrugMatrix | Cell Type: liver | Dose: 280.0 mg/kg | Time: 5 d Digitoxin | ID: CHEMBL254219 | Study: DrugMatrix | Cell Type: heart | Dose: 2.75 mg/kg | Time: 3 d Digoxin | ID: CHEMBL1751 | Study: DrugMatrix | Cell Type: liver | Dose: 11.0 mg/kg | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 2 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 8 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 2 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 8 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 8 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 3 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 6 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 9 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 240.0 mg/kg | Time: 3 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 240.0 mg/kg | Time: 6 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 240.0 mg/kg | Time: 9 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 240.0 mg/kg | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 800.0 mg/kg | Time: 3 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 800.0 mg/kg | Time: 6 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 800.0 mg/kg | Time: 9 h Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 800.0 mg/kg | Time: 1 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 4 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 8 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 15 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 29 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 240.0 mg/kg | Time: 4 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 240.0 mg/kg | Time: 8 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 240.0 mg/kg | Time: 15 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 240.0 mg/kg | Time: 29 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 800.0 mg/kg | Time: 4 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 800.0 mg/kg | Time: 8 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 800.0 mg/kg | Time: 15 d Diltiazem | ID: CHEMBL23 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 800.0 mg/kg | Time: 29 d Diphenhydramine | ID: CHEMBL657 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 263.0 μM | Time: 16 h Diphenhydramine | ID: CHEMBL657 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 263.0 μM | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 2 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 8 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 2 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 8 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 700.0 μM | Time: 8 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 700.0 μM | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3500.0 μM | Time: 8 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3500.0 μM | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 3 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 6 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 9 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 3 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 6 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 9 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 3 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 6 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 9 h Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 1 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 4 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 8 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 15 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 29 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 4 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 8 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 15 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 29 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 4 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 8 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 15 d Disopyramide | ID: CHEMBL517 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 29 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 2 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 8 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 8 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Disulfiram | ID: CHEMBL964 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Dobutamine | ID: CHEMBL926 | Study: DrugMatrix | Cell Type: heart | Dose: 15.0 mg/kg | Time: 1 d Dobutamine | ID: CHEMBL926 | Study: DrugMatrix | Cell Type: heart | Dose: 15.0 mg/kg | Time: 3 d Dobutamine | ID: CHEMBL926 | Study: DrugMatrix | Cell Type: heart | Dose: 15.0 mg/kg | Time: 5 d Doxepin | ID: CHEMBL101740 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 132.0 μM | Time: 16 h Doxepin | ID: CHEMBL101740 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 132.0 μM | Time: 1 d Doxofylline | ID: CHEMBL1527608 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 13500.0 μM | Time: 16 h Doxofylline | ID: CHEMBL1527608 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 13500.0 μM | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.08 μM | Time: 2 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.08 μM | Time: 8 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.08 μM | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 2 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 8 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 3 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 9 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 4 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 8 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 15 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.1 mg/kg | Time: 29 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 4 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 8 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 15 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 29 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 3 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 9 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 3 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 9 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 4 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 8 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 15 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.1 mg/kg | Time: 29 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 4 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 8 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 15 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.3 mg/kg | Time: 29 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Doxorubicin | ID: CHEMBL179 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: heart | Dose: 3.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: heart | Dose: 3.0 mg/kg | Time: 3 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: heart | Dose: 3.0 mg/kg | Time: 5 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.5 μM | Time: 16 h Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.5 μM | Time: 1 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: kidney | Dose: 3.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: kidney | Dose: 3.0 mg/kg | Time: 3 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: kidney | Dose: 3.0 mg/kg | Time: 5 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: liver | Dose: 0.65 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: liver | Dose: 0.65 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: liver | Dose: 0.65 mg/kg | Time: 3 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 6 h Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 1 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 3 d Doxorubicin | ID: CHEMBL53463 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 5 d Droperidol | ID: CHEMBL1108 | Study: DrugMatrix | Cell Type: heart | Dose: 94.0 mg/kg | Time: 1 d Econazole | ID: CHEMBL808 | Study: DrugMatrix | Cell Type: liver | Dose: 43.0 mg/kg | Time: 6 h Econazole | ID: CHEMBL808 | Study: DrugMatrix | Cell Type: liver | Dose: 43.0 mg/kg | Time: 1 d Econazole | ID: CHEMBL808 | Study: DrugMatrix | Cell Type: liver | Dose: 43.0 mg/kg | Time: 3 d Econazole | ID: CHEMBL808 | Study: DrugMatrix | Cell Type: liver | Dose: 43.0 mg/kg | Time: 5 d Econazole | ID: CHEMBL808 | Study: DrugMatrix | Cell Type: liver | Dose: 334.0 mg/kg | Time: 6 h Econazole | ID: CHEMBL808 | Study: DrugMatrix | Cell Type: liver | Dose: 334.0 mg/kg | Time: 1 d Econazole | ID: CHEMBL808 | Study: DrugMatrix | Cell Type: liver | Dose: 334.0 mg/kg | Time: 5 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 3 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 6 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 9 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 3 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 6 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 9 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 3 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 6 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 9 h Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 600.0 mg/kg | Time: 1 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Enalapril | ID: CHEMBL578 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Enalapril | ID: CHEMBL578 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Enoxacin | ID: CHEMBL826 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 6 h Enoxacin | ID: CHEMBL826 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 1 d Enoxacin | ID: CHEMBL826 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 3 d Enoxacin | ID: CHEMBL826 | Study: DrugMatrix | Cell Type: liver | Dose: 750.0 mg/kg | Time: 6 h Enoxacin | ID: CHEMBL826 | Study: DrugMatrix | Cell Type: liver | Dose: 750.0 mg/kg | Time: 1 d Enrofloxacin | ID: CHEMBL15511 | Study: DrugMatrix | Cell Type: kidney | Dose: 2000.0 mg/kg | Time: 1 d Enrofloxacin | ID: CHEMBL15511 | Study: DrugMatrix | Cell Type: kidney | Dose: 2000.0 mg/kg | Time: 3 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 10.0 μM | Time: 16 h Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 10.0 μM | Time: 1 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: kidney | Dose: 58.0 mg/kg | Time: 1 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: kidney | Dose: 58.0 mg/kg | Time: 3 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: kidney | Dose: 58.0 mg/kg | Time: 5 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: kidney | Dose: 116.0 mg/kg | Time: 1 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: kidney | Dose: 116.0 mg/kg | Time: 3 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: kidney | Dose: 116.0 mg/kg | Time: 5 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: liver | Dose: 58.0 mg/kg | Time: 1 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: liver | Dose: 58.0 mg/kg | Time: 3 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: liver | Dose: 58.0 mg/kg | Time: 5 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: liver | Dose: 116.0 mg/kg | Time: 1 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: liver | Dose: 116.0 mg/kg | Time: 3 d Erlotinib | ID: CHEMBL553 | Study: DrugMatrix | Cell Type: liver | Dose: 116.0 mg/kg | Time: 5 d Erythromycin | ID: CHEMBL532 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 1 d Erythromycin | ID: CHEMBL532 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 3 d Erythromycin | ID: CHEMBL532 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 5 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 2 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 8 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.0 μM | Time: 8 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.0 μM | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 8 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Erythromycin Ethylsuccinate | ID: CHEMBL1200688 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 16 h Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: kidney | Dose: 150.0 mg/kg | Time: 1 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: kidney | Dose: 150.0 mg/kg | Time: 3 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: kidney | Dose: 150.0 mg/kg | Time: 5 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 0.25 mg/kg | Time: 6 h Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 0.25 mg/kg | Time: 1 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 6 h Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 1 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 3 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 5 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 2.0 mg/kg | Time: 1 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 2.0 mg/kg | Time: 3 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 6 h Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 1 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 3 d Estradiol Benzoate | ID: CHEMBL282575 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 5 d Estriol | ID: CHEMBL193482 | Study: DrugMatrix | Cell Type: liver | Dose: 313.0 mg/kg | Time: 1 d Estriol | ID: CHEMBL193482 | Study: DrugMatrix | Cell Type: liver | Dose: 313.0 mg/kg | Time: 3 d Estriol | ID: CHEMBL193482 | Study: DrugMatrix | Cell Type: liver | Dose: 313.0 mg/kg | Time: 5 d Ethacrynic Acid | ID: CHEMBL1684247 | Study: DrugMatrix | Cell Type: kidney | Dose: 125.0 mg/kg | Time: 3 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 2 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 8 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 2 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 8 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 2 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 8 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 8 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 8 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Ethambutol | ID: CHEMBL44884 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Ethambutol | ID: CHEMBL44884 | Study: DrugMatrix | Cell Type: kidney | Dose: 998.0 mg/kg | Time: 3 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 3 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 6 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 9 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 3 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 6 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 9 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4000.0 mg/kg | Time: 3 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4000.0 mg/kg | Time: 6 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4000.0 mg/kg | Time: 9 h Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4000.0 mg/kg | Time: 1 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 4 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 8 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 15 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 29 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1200.0 mg/kg | Time: 4 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1200.0 mg/kg | Time: 8 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1200.0 mg/kg | Time: 15 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1200.0 mg/kg | Time: 29 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4000.0 mg/kg | Time: 4 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4000.0 mg/kg | Time: 8 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4000.0 mg/kg | Time: 15 d Ethanol | ID: CHEMBL545 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4000.0 mg/kg | Time: 29 d Ethanol | ID: CHEMBL545 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 180000.0 μM | Time: 16 h Ethanol | ID: CHEMBL545 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 180000.0 μM | Time: 1 d Ethanol | ID: CHEMBL545 | Study: DrugMatrix | Cell Type: kidney | Dose: 3000.0 mg/kg | Time: 3 d Ethanol | ID: CHEMBL545 | Study: DrugMatrix | Cell Type: kidney | Dose: 6000.0 mg/kg | Time: 3 d Ethanol | ID: CHEMBL545 | Study: DrugMatrix | Cell Type: liver | Dose: 6000.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 3 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 9 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 3 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 9 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 3 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 9 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Ethinylestradiol | ID: CHEMBL691 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 190.0 μM | Time: 16 h Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 190.0 μM | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 3 d Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 5 d Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 1480.0 mg/kg | Time: 6 h Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 1480.0 mg/kg | Time: 1 d Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 1480.0 mg/kg | Time: 3 d Ethinylestradiol | ID: CHEMBL691 | Study: DrugMatrix | Cell Type: liver | Dose: 1480.0 mg/kg | Time: 5 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 2 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 8 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 2 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 8 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Ethionamide | ID: CHEMBL1441 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 2 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 2 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 2 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 3 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 6 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 9 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 3 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 6 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 9 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 80.0 mg/kg | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 3 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 6 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 9 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 4 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 8 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 15 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 29 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 4 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 8 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 15 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 80.0 mg/kg | Time: 29 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 4 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 8 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 15 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 29 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 25.0 mg/kg | Time: 3 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 25.0 mg/kg | Time: 6 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 25.0 mg/kg | Time: 9 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 25.0 mg/kg | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 80.0 mg/kg | Time: 3 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 80.0 mg/kg | Time: 6 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 80.0 mg/kg | Time: 9 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 80.0 mg/kg | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 250.0 mg/kg | Time: 3 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 250.0 mg/kg | Time: 6 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 250.0 mg/kg | Time: 9 h Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 250.0 mg/kg | Time: 1 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 25.0 mg/kg | Time: 4 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 25.0 mg/kg | Time: 8 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 25.0 mg/kg | Time: 15 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 25.0 mg/kg | Time: 29 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 80.0 mg/kg | Time: 4 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 80.0 mg/kg | Time: 8 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 80.0 mg/kg | Time: 15 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 80.0 mg/kg | Time: 29 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 250.0 mg/kg | Time: 4 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 250.0 mg/kg | Time: 8 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 250.0 mg/kg | Time: 15 d Ethionine | ID: CHEMBL203187 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 250.0 mg/kg | Time: 29 d Ethisterone | ID: CHEMBL241694 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 1 d Ethisterone | ID: CHEMBL241694 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 3 d Ethisterone | ID: CHEMBL241694 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 5 d Ethylestrenol | ID: CHEMBL1200623 | Study: DrugMatrix | Cell Type: liver | Dose: 390.0 mg/kg | Time: 5 d Etidronic Acid | ID: CHEMBL871 | Study: DrugMatrix | Cell Type: heart | Dose: 1005.0 mg/kg | Time: 3 d Etidronic Acid | ID: CHEMBL871 | Study: DrugMatrix | Cell Type: heart | Dose: 1005.0 mg/kg | Time: 5 d Etidronic Acid | ID: CHEMBL871 | Study: DrugMatrix | Cell Type: muscle | Dose: 1005.0 mg/kg | Time: 3 d Etidronic Acid | ID: CHEMBL871 | Study: DrugMatrix | Cell Type: muscle | Dose: 1005.0 mg/kg | Time: 5 d Etodolac | ID: CHEMBL622 | Study: DrugMatrix | Cell Type: liver | Dose: 24.0 mg/kg | Time: 1 d Etodolac | ID: CHEMBL622 | Study: DrugMatrix | Cell Type: liver | Dose: 24.0 mg/kg | Time: 3 d Etodolac | ID: CHEMBL622 | Study: DrugMatrix | Cell Type: liver | Dose: 24.0 mg/kg | Time: 5 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 14.0 μM | Time: 2 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 14.0 μM | Time: 8 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 14.0 μM | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 70.0 μM | Time: 2 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 70.0 μM | Time: 8 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 70.0 μM | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 350.0 μM | Time: 2 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 350.0 μM | Time: 8 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 350.0 μM | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 66.0 μM | Time: 8 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 66.0 μM | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 330.0 μM | Time: 8 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 330.0 μM | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Etoposide | ID: CHEMBL44657 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Etoposide | ID: CHEMBL44657 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 16 h Etoposide | ID: CHEMBL44657 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 2 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 8 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 2 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 8 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 700.0 μM | Time: 2 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 700.0 μM | Time: 8 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 700.0 μM | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 8 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 700.0 μM | Time: 8 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 700.0 μM | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Famotidine | ID: CHEMBL902 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Famotidine | ID: CHEMBL902 | Study: DrugMatrix | Cell Type: heart | Dose: 1200.0 mg/kg | Time: 3 d Famotidine | ID: CHEMBL902 | Study: DrugMatrix | Cell Type: heart | Dose: 1200.0 mg/kg | Time: 5 d Famotidine | ID: CHEMBL902 | Study: DrugMatrix | Cell Type: muscle | Dose: 1200.0 mg/kg | Time: 3 d Famotidine | ID: CHEMBL902 | Study: DrugMatrix | Cell Type: muscle | Dose: 1200.0 mg/kg | Time: 5 d Fenbendazole | ID: CHEMBL37161 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 2 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 8 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 2 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 8 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 2 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 8 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 8 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Fenofibrate | ID: CHEMBL672 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: heart | Dose: 215.0 mg/kg | Time: 3 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: heart | Dose: 215.0 mg/kg | Time: 5 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 16 h Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: kidney | Dose: 43.0 mg/kg | Time: 6 h Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: kidney | Dose: 43.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: kidney | Dose: 43.0 mg/kg | Time: 3 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: kidney | Dose: 215.0 mg/kg | Time: 3 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: kidney | Dose: 215.0 mg/kg | Time: 5 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 43.0 mg/kg | Time: 6 h Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 43.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 43.0 mg/kg | Time: 5 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 6 h Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 3 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 7 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 215.0 mg/kg | Time: 6 h Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 215.0 mg/kg | Time: 1 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 215.0 mg/kg | Time: 3 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 215.0 mg/kg | Time: 5 d Fenofibrate | ID: CHEMBL981 | Study: DrugMatrix | Cell Type: liver | Dose: 430.0 mg/kg | Time: 5 d Fenoprofen | ID: CHEMBL1297 | Study: DrugMatrix | Cell Type: kidney | Dose: 52.0 mg/kg | Time: 1 d Fexofenadine | ID: CHEMBL17157 | Study: DrugMatrix | Cell Type: heart | Dose: 750.0 mg/kg | Time: 3 d Fexofenadine | ID: CHEMBL17157 | Study: DrugMatrix | Cell Type: heart | Dose: 750.0 mg/kg | Time: 5 d Finasteride | ID: CHEMBL710 | Study: DrugMatrix | Cell Type: liver | Dose: 800.0 mg/kg | Time: 3 d Finasteride | ID: CHEMBL710 | Study: DrugMatrix | Cell Type: liver | Dose: 800.0 mg/kg | Time: 5 d Flubendazole | ID: CHEMBL1454946 | Study: DrugMatrix | Cell Type: liver | Dose: 1200.0 mg/kg | Time: 1 d Fluconazole | ID: CHEMBL106 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 6 h Fluconazole | ID: CHEMBL106 | Study: DrugMatrix | Cell Type: liver | Dose: 394.0 mg/kg | Time: 6 h Fluconazole | ID: CHEMBL106 | Study: DrugMatrix | Cell Type: liver | Dose: 394.0 mg/kg | Time: 1 d Fluconazole | ID: CHEMBL106 | Study: DrugMatrix | Cell Type: liver | Dose: 394.0 mg/kg | Time: 3 d Fluconazole | ID: CHEMBL106 | Study: DrugMatrix | Cell Type: liver | Dose: 394.0 mg/kg | Time: 5 d Fludrocortisone | ID: CHEMBL1201010 | Study: DrugMatrix | Cell Type: heart | Dose: 125.0 mg/kg | Time: 1 d Fludrocortisone | ID: CHEMBL1201010 | Study: DrugMatrix | Cell Type: heart | Dose: 125.0 mg/kg | Time: 3 d Fludrocortisone | ID: CHEMBL1201010 | Study: DrugMatrix | Cell Type: heart | Dose: 125.0 mg/kg | Time: 5 d Fludrocortisone | ID: CHEMBL1201010 | Study: DrugMatrix | Cell Type: kidney | Dose: 125.0 mg/kg | Time: 1 d Fludrocortisone | ID: CHEMBL1201010 | Study: DrugMatrix | Cell Type: liver | Dose: 125.0 mg/kg | Time: 1 d Flunarizine | ID: CHEMBL30008 | Study: DrugMatrix | Cell Type: heart | Dose: 126.0 mg/kg | Time: 3 d Flunarizine | ID: CHEMBL30008 | Study: DrugMatrix | Cell Type: heart | Dose: 126.0 mg/kg | Time: 5 d Flunarizine | ID: CHEMBL30008 | Study: DrugMatrix | Cell Type: muscle | Dose: 126.0 mg/kg | Time: 3 d Flunarizine | ID: CHEMBL30008 | Study: DrugMatrix | Cell Type: muscle | Dose: 126.0 mg/kg | Time: 5 d Fluocinolone Acetonide | ID: CHEMBL989 | Study: DrugMatrix | Cell Type: heart | Dose: 2.5 mg/kg | Time: 1 d Fluocinolone Acetonide | ID: CHEMBL989 | Study: DrugMatrix | Cell Type: heart | Dose: 2.5 mg/kg | Time: 3 d Fluocinolone Acetonide | ID: CHEMBL989 | Study: DrugMatrix | Cell Type: heart | Dose: 2.5 mg/kg | Time: 5 d Fluocinolone Acetonide | ID: CHEMBL989 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 1 d Fluocinolone Acetonide | ID: CHEMBL989 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 3 d Fluocinolone Acetonide | ID: CHEMBL989 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 5 d Fluoxetine | ID: CHEMBL41 | Study: DrugMatrix | Cell Type: heart | Dose: 52.0 mg/kg | Time: 1 d Fluoxetine | ID: CHEMBL41 | Study: DrugMatrix | Cell Type: heart | Dose: 52.0 mg/kg | Time: 5 d Fluoxetine | ID: CHEMBL41 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 58.0 μM | Time: 16 h Fluoxetine | ID: CHEMBL41 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 58.0 μM | Time: 1 d Fluoxetine | ID: CHEMBL41 | Study: DrugMatrix | Cell Type: kidney | Dose: 52.0 mg/kg | Time: 1 d Fluoxetine | ID: CHEMBL41 | Study: DrugMatrix | Cell Type: kidney | Dose: 52.0 mg/kg | Time: 3 d Fluoxetine | ID: CHEMBL41 | Study: DrugMatrix | Cell Type: kidney | Dose: 52.0 mg/kg | Time: 5 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 2 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 8 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 2 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 8 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 2 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 8 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 2 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 8 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 3 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 6 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 9 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 3 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 6 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 9 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 4 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 8 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 15 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 29 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Fluphenazine | ID: CHEMBL726 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Fluphenazine | ID: CHEMBL726 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 45.0 μM | Time: 16 h Fluphenazine | ID: CHEMBL726 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 45.0 μM | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 6 h Fluphenazine | ID: CHEMBL726 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 1 d Fluphenazine | ID: CHEMBL726 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 3 d Fluphenazine | ID: CHEMBL726 | Study: DrugMatrix | Cell Type: liver | Dose: 22.0 mg/kg | Time: 6 h Fluphenazine | ID: CHEMBL726 | Study: DrugMatrix | Cell Type: liver | Dose: 22.0 mg/kg | Time: 1 d Flurbiprofen | ID: CHEMBL563 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 1 d Flurbiprofen | ID: CHEMBL563 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 3 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 2 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 8 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.0 μM | Time: 2 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.0 μM | Time: 8 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.0 μM | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 2 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 2 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Flutamide | ID: CHEMBL806 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: kidney | Dose: 5.0 mg/kg | Time: 6 h Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: kidney | Dose: 5.0 mg/kg | Time: 1 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: kidney | Dose: 5.0 mg/kg | Time: 3 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: kidney | Dose: 94.0 mg/kg | Time: 3 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: kidney | Dose: 94.0 mg/kg | Time: 5 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: liver | Dose: 5.0 mg/kg | Time: 6 h Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: liver | Dose: 5.0 mg/kg | Time: 1 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: liver | Dose: 5.0 mg/kg | Time: 5 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: liver | Dose: 94.0 mg/kg | Time: 6 h Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: liver | Dose: 94.0 mg/kg | Time: 1 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: liver | Dose: 94.0 mg/kg | Time: 3 d Fluvastatin | ID: CHEMBL1078 | Study: DrugMatrix | Cell Type: liver | Dose: 94.0 mg/kg | Time: 5 d Fomepizole | ID: CHEMBL1308 | Study: DrugMatrix | Cell Type: kidney | Dose: 155.0 mg/kg | Time: 1 d Fomepizole | ID: CHEMBL1308 | Study: DrugMatrix | Cell Type: kidney | Dose: 155.0 mg/kg | Time: 3 d Furan | ID: CHEMBL278980 | Study: DrugMatrix | Cell Type: heart | Dose: 24.0 mg/kg | Time: 1 d Furan | ID: CHEMBL278980 | Study: DrugMatrix | Cell Type: heart | Dose: 24.0 mg/kg | Time: 3 d Furan | ID: CHEMBL278980 | Study: DrugMatrix | Cell Type: heart | Dose: 24.0 mg/kg | Time: 5 d Furan | ID: CHEMBL278980 | Study: DrugMatrix | Cell Type: kidney | Dose: 24.0 mg/kg | Time: 1 d Furan | ID: CHEMBL278980 | Study: DrugMatrix | Cell Type: kidney | Dose: 24.0 mg/kg | Time: 3 d Furan | ID: CHEMBL278980 | Study: DrugMatrix | Cell Type: kidney | Dose: 24.0 mg/kg | Time: 5 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 2 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 8 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 2 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 8 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 500.0 μM | Time: 8 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 500.0 μM | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2500.0 μM | Time: 8 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2500.0 μM | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Furosemide | ID: CHEMBL35 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Furosemide | ID: CHEMBL35 | Study: DrugMatrix | Cell Type: kidney | Dose: 375.0 mg/kg | Time: 5 d Gabapentin | ID: CHEMBL940 | Study: DrugMatrix | Cell Type: heart | Dose: 2500.0 mg/kg | Time: 3 d Gabapentin | ID: CHEMBL940 | Study: DrugMatrix | Cell Type: heart | Dose: 2500.0 mg/kg | Time: 5 d Gabapentin | ID: CHEMBL940 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 16 h Gabapentin | ID: CHEMBL940 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 1 d Gabapentin | ID: CHEMBL940 | Study: DrugMatrix | Cell Type: muscle | Dose: 2500.0 mg/kg | Time: 3 d Gabapentin | ID: CHEMBL940 | Study: DrugMatrix | Cell Type: muscle | Dose: 2500.0 mg/kg | Time: 5 d Gadopentetate Dimeglumine | ID: CHEMBL1200431 | Study: DrugMatrix | Cell Type: kidney | Dose: 125.0 mg/kg | Time: 5 d Gatifloxacin | ID: CHEMBL251670 | Study: DrugMatrix | Cell Type: kidney | Dose: 770.0 mg/kg | Time: 1 d Gatifloxacin | ID: CHEMBL251670 | Study: DrugMatrix | Cell Type: kidney | Dose: 770.0 mg/kg | Time: 5 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 35.0 μM | Time: 16 h Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 35.0 μM | Time: 1 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: kidney | Dose: 58.0 mg/kg | Time: 1 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: kidney | Dose: 58.0 mg/kg | Time: 3 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: kidney | Dose: 58.0 mg/kg | Time: 5 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: kidney | Dose: 116.0 mg/kg | Time: 1 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: kidney | Dose: 116.0 mg/kg | Time: 3 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: kidney | Dose: 116.0 mg/kg | Time: 5 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: liver | Dose: 58.0 mg/kg | Time: 1 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: liver | Dose: 58.0 mg/kg | Time: 3 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: liver | Dose: 58.0 mg/kg | Time: 5 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: liver | Dose: 116.0 mg/kg | Time: 1 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: liver | Dose: 116.0 mg/kg | Time: 3 d Gefitinib | ID: CHEMBL939 | Study: DrugMatrix | Cell Type: liver | Dose: 116.0 mg/kg | Time: 5 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 2 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 8 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 2 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 8 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 100.0 μM | Time: 2 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 100.0 μM | Time: 8 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 100.0 μM | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Gemfibrozil | ID: CHEMBL457 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2000.0 μM | Time: 16 h Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2000.0 μM | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 6 h Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: kidney | Dose: 100.0 mg/kg | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: kidney | Dose: 700.0 mg/kg | Time: 7 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 6 h Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 3 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 7 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 6 h Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 1 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 3 d Gemfibrozil | ID: CHEMBL457 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 7 d Genistein | ID: CHEMBL1209088 | Study: DrugMatrix | Cell Type: liver | Dose: 20.0 mg/kg | Time: 6 h Genistein | ID: CHEMBL1209088 | Study: DrugMatrix | Cell Type: liver | Dose: 20.0 mg/kg | Time: 5 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 mg/ml | Time: 2 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 mg/ml | Time: 8 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 mg/ml | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 mg/ml | Time: 2 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 mg/ml | Time: 8 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 mg/ml | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 mg/ml | Time: 2 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 mg/ml | Time: 8 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 mg/ml | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Gentamicin | ID: CHEMBL1201259 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 16 h Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 1 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2900.0 μM | Time: 16 h Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2900.0 μM | Time: 1 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: kidney | Dose: 40.0 mg/kg | Time: 5 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: kidney | Dose: 267.0 mg/kg | Time: 1 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: kidney | Dose: 267.0 mg/kg | Time: 3 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: kidney | Dose: 267.0 mg/kg | Time: 5 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: liver | Dose: 267.0 mg/kg | Time: 3 d Gentamycin | ID: CHEMBL220884 | Study: DrugMatrix | Cell Type: liver | Dose: 267.0 mg/kg | Time: 5 d Gentian Violet | ID: CHEMBL459265 | Study: DrugMatrix | Cell Type: liver | Dose: 18.0 mg/kg | Time: 1 d Gentian Violet | ID: CHEMBL459265 | Study: DrugMatrix | Cell Type: liver | Dose: 18.0 mg/kg | Time: 3 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 2 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 8 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 2 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 8 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Glibenclamide | ID: CHEMBL472 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Glibenclamide | ID: CHEMBL472 | Study: DrugMatrix | Cell Type: muscle | Dose: 1500.0 mg/kg | Time: 3 d Glibenclamide | ID: CHEMBL472 | Study: DrugMatrix | Cell Type: muscle | Dose: 1500.0 mg/kg | Time: 5 d Glipizide | ID: CHEMBL1073 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 6 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 2 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 8 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 2 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 8 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 2 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 8 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 2 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 8 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Griseofulvin | ID: CHEMBL562 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Griseofulvin | ID: CHEMBL562 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 75.0 μM | Time: 16 h Griseofulvin | ID: CHEMBL562 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 75.0 μM | Time: 1 d Guanethidine | ID: CHEMBL765 | Study: DrugMatrix | Cell Type: heart | Dose: 132.0 mg/kg | Time: 3 d Guanethidine | ID: CHEMBL765 | Study: DrugMatrix | Cell Type: heart | Dose: 132.0 mg/kg | Time: 5 d Guanethidine | ID: CHEMBL765 | Study: DrugMatrix | Cell Type: muscle | Dose: 132.0 mg/kg | Time: 3 d Guanethidine | ID: CHEMBL765 | Study: DrugMatrix | Cell Type: muscle | Dose: 132.0 mg/kg | Time: 5 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 2 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 8 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 2 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 8 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Haloperidol | ID: CHEMBL54 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Haloperidol | ID: CHEMBL54 | Study: DrugMatrix | Cell Type: heart | Dose: 21.0 mg/kg | Time: 3 d Haloperidol | ID: CHEMBL54 | Study: DrugMatrix | Cell Type: heart | Dose: 21.0 mg/kg | Time: 5 d Haloperidol | ID: CHEMBL54 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 77.0 μM | Time: 16 h Haloperidol | ID: CHEMBL54 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 77.0 μM | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.2 μM | Time: 2 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.2 μM | Time: 8 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.2 μM | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 2 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 8 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 2 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 3 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 6 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 9 h Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 1 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Hexachlorobenzene | ID: CHEMBL228514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Hexachlorobuta-1,3-Diene | ID: CHEMBL389950 | Study: DrugMatrix | Cell Type: kidney | Dose: 50.0 mg/kg | Time: 1 d Hexachlorobuta-1,3-Diene | ID: CHEMBL389950 | Study: DrugMatrix | Cell Type: kidney | Dose: 50.0 mg/kg | Time: 3 d Hexachlorobuta-1,3-Diene | ID: CHEMBL389950 | Study: DrugMatrix | Cell Type: kidney | Dose: 50.0 mg/kg | Time: 5 d Hexachlorophene | ID: CHEMBL496 | Study: DrugMatrix | Cell Type: liver | Dose: 8.0 mg/kg | Time: 1 d Hexamethylmelamine | ID: CHEMBL1455 | Study: DrugMatrix | Cell Type: liver | Dose: 13.0 mg/kg | Time: 6 h Hexamethylmelamine | ID: CHEMBL1455 | Study: DrugMatrix | Cell Type: liver | Dose: 13.0 mg/kg | Time: 1 d Hexamethylmelamine | ID: CHEMBL1455 | Study: DrugMatrix | Cell Type: liver | Dose: 13.0 mg/kg | Time: 3 d Hexamethylmelamine | ID: CHEMBL1455 | Study: DrugMatrix | Cell Type: liver | Dose: 13.0 mg/kg | Time: 5 d Hexamethylmelamine | ID: CHEMBL1455 | Study: DrugMatrix | Cell Type: liver | Dose: 40.0 mg/kg | Time: 6 h Hexamethylmelamine | ID: CHEMBL1455 | Study: DrugMatrix | Cell Type: liver | Dose: 40.0 mg/kg | Time: 1 d Hexamethylmelamine | ID: CHEMBL1455 | Study: DrugMatrix | Cell Type: liver | Dose: 40.0 mg/kg | Time: 3 d Hydrazine | ID: CHEMBL1237174 | Study: DrugMatrix | Cell Type: liver | Dose: 45.0 mg/kg | Time: 6 h Hydrazine | ID: CHEMBL1237174 | Study: DrugMatrix | Cell Type: liver | Dose: 45.0 mg/kg | Time: 3 d Hydrazine | ID: CHEMBL1237174 | Study: DrugMatrix | Cell Type: liver | Dose: 45.0 mg/kg | Time: 5 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: heart | Dose: 56.0 mg/kg | Time: 1 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: heart | Dose: 56.0 mg/kg | Time: 3 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: heart | Dose: 56.0 mg/kg | Time: 5 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: kidney | Dose: 56.0 mg/kg | Time: 1 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: kidney | Dose: 56.0 mg/kg | Time: 3 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: kidney | Dose: 56.0 mg/kg | Time: 5 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: liver | Dose: 56.0 mg/kg | Time: 1 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: liver | Dose: 56.0 mg/kg | Time: 3 d Hydrcortisone | ID: CHEMBL389621 | Study: DrugMatrix | Cell Type: liver | Dose: 56.0 mg/kg | Time: 5 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 2 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 8 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 2 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 8 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 2 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 8 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 8 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 8 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Hydroxyzine | ID: CHEMBL896 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 2 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 8 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 8 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 3 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 6 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 9 h Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 1 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Ibuprofen | ID: CHEMBL521 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Ibuprofen | ID: CHEMBL427526 | Study: DrugMatrix | Cell Type: kidney | Dose: 54.0 mg/kg | Time: 3 d Ibuprofen | ID: CHEMBL427526 | Study: DrugMatrix | Cell Type: kidney | Dose: 263.0 mg/kg | Time: 3 d Ibuprofen | ID: CHEMBL427526 | Study: DrugMatrix | Cell Type: kidney | Dose: 263.0 mg/kg | Time: 5 d Ibuprofen | ID: CHEMBL427526 | Study: DrugMatrix | Cell Type: liver | Dose: 263.0 mg/kg | Time: 1 d Ibuprofen | ID: CHEMBL427526 | Study: DrugMatrix | Cell Type: liver | Dose: 263.0 mg/kg | Time: 3 d Ibuprofen | ID: CHEMBL427526 | Study: DrugMatrix | Cell Type: liver | Dose: 263.0 mg/kg | Time: 5 d Idarubicin | ID: CHEMBL1117 | Study: DrugMatrix | Cell Type: heart | Dose: 0.625 mg/kg | Time: 1 d Idarubicin | ID: CHEMBL1117 | Study: DrugMatrix | Cell Type: heart | Dose: 0.625 mg/kg | Time: 3 d Idarubicin | ID: CHEMBL1117 | Study: DrugMatrix | Cell Type: heart | Dose: 0.625 mg/kg | Time: 5 d Idarubicin | ID: CHEMBL1117 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.5 μM | Time: 16 h Idarubicin | ID: CHEMBL1117 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.5 μM | Time: 1 d Idebenone | ID: CHEMBL252556 | Study: DrugMatrix | Cell Type: liver | Dose: 2500.0 mg/kg | Time: 6 h Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: heart | Dose: 143.0 mg/kg | Time: 3 d Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: heart | Dose: 143.0 mg/kg | Time: 5 d Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 11000.0 μM | Time: 16 h Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 11000.0 μM | Time: 1 d Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: liver | Dose: 17.0 mg/kg | Time: 6 h Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: liver | Dose: 17.0 mg/kg | Time: 1 d Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: liver | Dose: 143.0 mg/kg | Time: 6 h Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: liver | Dose: 143.0 mg/kg | Time: 1 d Ifosfamide | ID: CHEMBL1024 | Study: DrugMatrix | Cell Type: liver | Dose: 143.0 mg/kg | Time: 3 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: heart | Dose: 15.0 mg/kg | Time: 1 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: heart | Dose: 15.0 mg/kg | Time: 3 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: heart | Dose: 15.0 mg/kg | Time: 5 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: heart | Dose: 150.0 mg/kg | Time: 1 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: heart | Dose: 150.0 mg/kg | Time: 3 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: heart | Dose: 150.0 mg/kg | Time: 5 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 15.0 μM | Time: 16 h Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 15.0 μM | Time: 1 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: kidney | Dose: 15.0 mg/kg | Time: 1 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: kidney | Dose: 15.0 mg/kg | Time: 3 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: kidney | Dose: 15.0 mg/kg | Time: 5 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: kidney | Dose: 150.0 mg/kg | Time: 1 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: kidney | Dose: 150.0 mg/kg | Time: 3 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: kidney | Dose: 150.0 mg/kg | Time: 5 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: liver | Dose: 15.0 mg/kg | Time: 1 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: liver | Dose: 15.0 mg/kg | Time: 3 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: liver | Dose: 15.0 mg/kg | Time: 5 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 1 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 3 d Imatinib | ID: CHEMBL941 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 5 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 2 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 8 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 2 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 8 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Imipramine | ID: CHEMBL11 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 2 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 8 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 8.0 μM | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 2 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 8 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 2 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 8 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 3 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 6 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 9 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 5.0 mg/kg | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 4 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 8 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 15 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.5 mg/kg | Time: 29 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.6 mg/kg | Time: 4 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.6 mg/kg | Time: 8 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.6 mg/kg | Time: 15 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.6 mg/kg | Time: 29 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 4 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 8 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 15 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.5 mg/kg | Time: 3 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.5 mg/kg | Time: 6 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.5 mg/kg | Time: 9 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.5 mg/kg | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.6 mg/kg | Time: 3 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.6 mg/kg | Time: 6 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.6 mg/kg | Time: 9 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1.6 mg/kg | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 3 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 6 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 9 h Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 5.0 mg/kg | Time: 1 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.5 mg/kg | Time: 4 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.5 mg/kg | Time: 8 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.5 mg/kg | Time: 15 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.5 mg/kg | Time: 29 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.6 mg/kg | Time: 4 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.6 mg/kg | Time: 8 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.6 mg/kg | Time: 15 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1.6 mg/kg | Time: 29 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 5.0 mg/kg | Time: 4 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 5.0 mg/kg | Time: 8 d Indomethacin | ID: CHEMBL6 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 5.0 mg/kg | Time: 15 d Indomethacin | ID: CHEMBL6 | Study: DrugMatrix | Cell Type: heart | Dose: 9.6 mg/kg | Time: 3 d Indomethacin | ID: CHEMBL6 | Study: DrugMatrix | Cell Type: heart | Dose: 9.6 mg/kg | Time: 5 d Indomethacin | ID: CHEMBL6 | Study: DrugMatrix | Cell Type: kidney | Dose: 4.5 mg/kg | Time: 3 d Indomethacin | ID: CHEMBL6 | Study: DrugMatrix | Cell Type: kidney | Dose: 9.6 mg/kg | Time: 3 d Indomethacin | ID: CHEMBL6 | Study: DrugMatrix | Cell Type: kidney | Dose: 9.6 mg/kg | Time: 5 d Indomethacin | ID: CHEMBL25725 | Study: DrugMatrix | Cell Type: liver | Dose: 12.0 mg/kg | Time: 6 h Indomethacin | ID: CHEMBL25725 | Study: DrugMatrix | Cell Type: liver | Dose: 12.0 mg/kg | Time: 3 d Indomethacin | ID: CHEMBL25725 | Study: DrugMatrix | Cell Type: liver | Dose: 12.0 mg/kg | Time: 5 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 240.0 μM | Time: 8 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 240.0 μM | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1200.0 μM | Time: 8 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1200.0 μM | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 3 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 6 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 9 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Iproniazid | ID: CHEMBL92401 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Isoeugenol | ID: CHEMBL445206 | Study: DrugMatrix | Cell Type: kidney | Dose: 1560.0 mg/kg | Time: 1 d Isoeugenol | ID: CHEMBL445206 | Study: DrugMatrix | Cell Type: kidney | Dose: 1560.0 mg/kg | Time: 3 d Isoeugenol | ID: CHEMBL445206 | Study: DrugMatrix | Cell Type: kidney | Dose: 1560.0 mg/kg | Time: 5 d Isoeugenol | ID: CHEMBL445206 | Study: DrugMatrix | Cell Type: liver | Dose: 1560.0 mg/kg | Time: 1 d Isoeugenol | ID: CHEMBL445206 | Study: DrugMatrix | Cell Type: liver | Dose: 1560.0 mg/kg | Time: 3 d Isoeugenol | ID: CHEMBL445206 | Study: DrugMatrix | Cell Type: liver | Dose: 1560.0 mg/kg | Time: 5 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 2 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 2 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 2 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Isoniazid | ID: CHEMBL64 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Isoprenaline | ID: CHEMBL434 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 1 d Isoprenaline | ID: CHEMBL434 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 3 d Isoprenaline | ID: CHEMBL434 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 5 d Isoprenaline | ID: CHEMBL434 | Study: DrugMatrix | Cell Type: heart | Dose: 4.2 mg/kg | Time: 3 d Isoprenaline | ID: CHEMBL434 | Study: DrugMatrix | Cell Type: heart | Dose: 4.2 mg/kg | Time: 5 d Isotretinoin | ID: CHEMBL547 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 16 h Isotretinoin | ID: CHEMBL547 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 1 d Isotretinoin | ID: CHEMBL547 | Study: DrugMatrix | Cell Type: liver | Dose: 13.0 mg/kg | Time: 6 h Isotretinoin | ID: CHEMBL547 | Study: DrugMatrix | Cell Type: liver | Dose: 13.0 mg/kg | Time: 1 d Isotretinoin | ID: CHEMBL547 | Study: DrugMatrix | Cell Type: liver | Dose: 13.0 mg/kg | Time: 3 d Isotretinoin | ID: CHEMBL547 | Study: DrugMatrix | Cell Type: liver | Dose: 125.0 mg/kg | Time: 6 h Itraconazole | ID: CHEMBL22587 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 10.0 μM | Time: 16 h Itraconazole | ID: CHEMBL22587 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 10.0 μM | Time: 1 d Itraconazole | ID: CHEMBL22587 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 6 h Itraconazole | ID: CHEMBL22587 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 1 d Itraconazole | ID: CHEMBL22587 | Study: DrugMatrix | Cell Type: liver | Dose: 1093.0 mg/kg | Time: 6 h Itraconazole | ID: CHEMBL22587 | Study: DrugMatrix | Cell Type: liver | Dose: 1093.0 mg/kg | Time: 1 d Itraconazole | ID: CHEMBL22587 | Study: DrugMatrix | Cell Type: liver | Dose: 1093.0 mg/kg | Time: 5 d Kanamycin A | ID: CHEMBL1384 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 6584.0 μM | Time: 16 h Kanamycin A | ID: CHEMBL1384 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 6584.0 μM | Time: 1 d Kanamycin A | ID: CHEMBL1384 | Study: DrugMatrix | Cell Type: kidney | Dose: 225.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 2 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 8 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 2 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 2 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ketoconazole | ID: CHEMBL75 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ketoconazole | ID: CHEMBL295698 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 90.0 μM | Time: 16 h Ketoconazole | ID: CHEMBL295698 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 90.0 μM | Time: 1 d Ketoconazole | ID: CHEMBL295698 | Study: DrugMatrix | Cell Type: liver | Dose: 114.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL295698 | Study: DrugMatrix | Cell Type: liver | Dose: 114.0 mg/kg | Time: 5 d Ketoconazole | ID: CHEMBL295698 | Study: DrugMatrix | Cell Type: liver | Dose: 227.0 mg/kg | Time: 6 h Ketoconazole | ID: CHEMBL295698 | Study: DrugMatrix | Cell Type: liver | Dose: 227.0 mg/kg | Time: 1 d Ketoconazole | ID: CHEMBL295698 | Study: DrugMatrix | Cell Type: liver | Dose: 227.0 mg/kg | Time: 3 d Ketorolac | ID: CHEMBL469 | Study: DrugMatrix | Cell Type: liver | Dose: 48.0 mg/kg | Time: 1 d Ketorolac | ID: CHEMBL469 | Study: DrugMatrix | Cell Type: liver | Dose: 48.0 mg/kg | Time: 3 d Ketorolac | ID: CHEMBL469 | Study: DrugMatrix | Cell Type: liver | Dose: 48.0 mg/kg | Time: 5 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.6 μM | Time: 2 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.6 μM | Time: 8 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.6 μM | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 2 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 8 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 28.0 μM | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 2 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 8 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 140.0 μM | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.6 μM | Time: 2 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.6 μM | Time: 8 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.6 μM | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 28.0 μM | Time: 2 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 28.0 μM | Time: 8 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 28.0 μM | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 2 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 8 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 140.0 μM | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 3 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 6 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 9 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 3 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 6 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 9 h Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 1 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 4 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 8 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 15 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 29 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 4 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 8 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 15 d Labetalol | ID: CHEMBL429 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 29 d Labetalol | ID: CHEMBL429 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 16 h Labetalol | ID: CHEMBL429 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Lansoprazole | ID: CHEMBL480 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 240.0 μM | Time: 16 h Lansoprazole | ID: CHEMBL480 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 240.0 μM | Time: 1 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 2.0 mg/kg | Time: 5 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 200.0 mg/kg | Time: 6 h Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 200.0 mg/kg | Time: 1 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 200.0 mg/kg | Time: 3 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 200.0 mg/kg | Time: 5 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 600.0 mg/kg | Time: 1 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 600.0 mg/kg | Time: 3 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: kidney | Dose: 600.0 mg/kg | Time: 5 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 3 d Lead Diacetate | ID: CHEMBL1909062 | Study: DrugMatrix | Cell Type: liver | Dose: 600.0 mg/kg | Time: 5 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: kidney | Dose: 30.0 mg/kg | Time: 6 h Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: kidney | Dose: 30.0 mg/kg | Time: 3 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 1 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 3 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 5 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 6 h Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 1 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 6 h Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 1 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 3 d Leflunomide | ID: CHEMBL960 | Study: DrugMatrix | Cell Type: liver | Dose: 60.0 mg/kg | Time: 5 d Letrozole | ID: CHEMBL1444 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 6 h Letrozole | ID: CHEMBL1444 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 1 d Letrozole | ID: CHEMBL1444 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 3 d Letrozole | ID: CHEMBL1444 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 5 d Lipopolysaccharide | ID: CHEMBL1909064 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.25 mg/kg | Time: 1 d Lipopolysaccharide | ID: CHEMBL1909064 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.25 mg/kg | Time: 3 d Lipopolysaccharide | ID: CHEMBL1909064 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.25 mg/kg | Time: 5 d Lipopolysaccharide | ID: CHEMBL1909064 | Study: DrugMatrix | Cell Type: liver | Dose: 1.25 mg/kg | Time: 6 h Lipopolysaccharide | ID: CHEMBL1909064 | Study: DrugMatrix | Cell Type: liver | Dose: 1.25 mg/kg | Time: 1 d Lipopolysaccharide | ID: CHEMBL1909064 | Study: DrugMatrix | Cell Type: liver | Dose: 1.25 mg/kg | Time: 3 d Lipopolysaccharide | ID: CHEMBL1909064 | Study: DrugMatrix | Cell Type: liver | Dose: 1.25 mg/kg | Time: 5 d Lithocholic Acid | ID: CHEMBL1478 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 74.0 μM | Time: 16 h Lithocholic Acid | ID: CHEMBL1478 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 74.0 μM | Time: 1 d Lomefloxacin | ID: CHEMBL561 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.8 μM | Time: 2 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.8 μM | Time: 8 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.8 μM | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 2 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 8 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.8 μM | Time: 2 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.8 μM | Time: 8 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.8 μM | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 2 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 8 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 2 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.6 mg/kg | Time: 3 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.6 mg/kg | Time: 6 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.6 mg/kg | Time: 9 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 0.6 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 3 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 6 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 9 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2.0 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 3 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 6 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 9 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.6 mg/kg | Time: 4 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.6 mg/kg | Time: 8 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.6 mg/kg | Time: 15 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.6 mg/kg | Time: 29 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 4 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 8 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 15 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 2.0 mg/kg | Time: 29 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.6 mg/kg | Time: 3 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.6 mg/kg | Time: 6 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.6 mg/kg | Time: 9 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 0.6 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2.0 mg/kg | Time: 3 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2.0 mg/kg | Time: 6 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2.0 mg/kg | Time: 9 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2.0 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 3 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 6 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 9 h Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 6.0 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.6 mg/kg | Time: 4 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.6 mg/kg | Time: 8 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.6 mg/kg | Time: 15 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 0.6 mg/kg | Time: 29 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 4 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 8 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 15 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 2.0 mg/kg | Time: 29 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Lomustine | ID: CHEMBL514 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 560.0 μM | Time: 16 h Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 560.0 μM | Time: 1 d Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: liver | Dose: 4.2 mg/kg | Time: 6 h Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: liver | Dose: 4.2 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: liver | Dose: 4.2 mg/kg | Time: 3 d Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: liver | Dose: 4.2 mg/kg | Time: 5 d Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: liver | Dose: 8.75 mg/kg | Time: 1 d Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: liver | Dose: 8.75 mg/kg | Time: 3 d Lomustine | ID: CHEMBL514 | Study: DrugMatrix | Cell Type: liver | Dose: 8.75 mg/kg | Time: 5 d Lorazepam | ID: CHEMBL249262 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 1 d Lorazepam | ID: CHEMBL249262 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d Lorazepam | ID: CHEMBL249262 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 5 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 3 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 6 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 9 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1.0 mg/kg | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 4 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 8 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 15 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 0.3 mg/kg | Time: 29 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 4 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 8 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 15 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1.0 mg/kg | Time: 29 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Lornoxicam | ID: CHEMBL1096619 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Losartan | ID: CHEMBL186572 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 1 d Losartan | ID: CHEMBL186572 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 3 d Losartan | ID: CHEMBL186572 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 5 d Losartan | ID: CHEMBL186572 | Study: DrugMatrix | Cell Type: muscle | Dose: 1000.0 mg/kg | Time: 3 d Losartan | ID: CHEMBL186572 | Study: DrugMatrix | Cell Type: muscle | Dose: 1000.0 mg/kg | Time: 5 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: kidney | Dose: 450.0 mg/kg | Time: 6 h Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: kidney | Dose: 450.0 mg/kg | Time: 1 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 1 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 3 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: liver | Dose: 450.0 mg/kg | Time: 6 h Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: liver | Dose: 450.0 mg/kg | Time: 1 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: liver | Dose: 450.0 mg/kg | Time: 5 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 1 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 3 d Lovastatin | ID: CHEMBL503 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 5 d Loxoprofen | ID: CHEMBL19299 | Study: DrugMatrix | Cell Type: kidney | Dose: 18.0 mg/kg | Time: 6 h Loxoprofen | ID: CHEMBL19299 | Study: DrugMatrix | Cell Type: kidney | Dose: 18.0 mg/kg | Time: 1 d Loxoprofen | ID: CHEMBL19299 | Study: DrugMatrix | Cell Type: kidney | Dose: 18.0 mg/kg | Time: 5 d Maprotiline | ID: CHEMBL21731 | Study: DrugMatrix | Cell Type: heart | Dose: 380.0 mg/kg | Time: 1 d Marimastat | ID: CHEMBL279785 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 16 h Marimastat | ID: CHEMBL279785 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 1 d Mebendazole | ID: CHEMBL685 | Study: DrugMatrix | Cell Type: liver | Dose: 714.0 mg/kg | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 2 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 8 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 2 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 8 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 2 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 8 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 150.0 μM | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 8 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Mefenamic Acid | ID: CHEMBL686 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Mefenamic Acid | ID: CHEMBL686 | Study: DrugMatrix | Cell Type: kidney | Dose: 93.0 mg/kg | Time: 1 d Mefenamic Acid | ID: CHEMBL686 | Study: DrugMatrix | Cell Type: kidney | Dose: 93.0 mg/kg | Time: 3 d Mefenamic Acid | ID: CHEMBL686 | Study: DrugMatrix | Cell Type: kidney | Dose: 93.0 mg/kg | Time: 5 d Megestrol Acetate | ID: CHEMBL1201139 | Study: DrugMatrix | Cell Type: liver | Dose: 132.0 mg/kg | Time: 1 d Megestrol Acetate | ID: CHEMBL1201139 | Study: DrugMatrix | Cell Type: liver | Dose: 132.0 mg/kg | Time: 5 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 2 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 8 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Meloxicam | ID: CHEMBL599 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Meloxicam | ID: CHEMBL599 | Study: DrugMatrix | Cell Type: kidney | Dose: 33.0 mg/kg | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: DrugMatrix | Cell Type: liver | Dose: 33.0 mg/kg | Time: 6 h Meloxicam | ID: CHEMBL599 | Study: DrugMatrix | Cell Type: liver | Dose: 33.0 mg/kg | Time: 1 d Meloxicam | ID: CHEMBL599 | Study: DrugMatrix | Cell Type: liver | Dose: 33.0 mg/kg | Time: 3 d Meloxicam | ID: CHEMBL599 | Study: DrugMatrix | Cell Type: liver | Dose: 33.0 mg/kg | Time: 5 d Mercaptopurine | ID: CHEMBL1425 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.5 μM | Time: 16 h Mercaptopurine | ID: CHEMBL1425 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.5 μM | Time: 1 d Mercaptopurine | ID: CHEMBL1425 | Study: DrugMatrix | Cell Type: liver | Dose: 25.0 mg/kg | Time: 3 d Mercaptopurine | ID: CHEMBL1425 | Study: DrugMatrix | Cell Type: liver | Dose: 25.0 mg/kg | Time: 5 d Mestranol | ID: CHEMBL1201151 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 1 d Mestranol | ID: CHEMBL1201151 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 3 d Mestranol | ID: CHEMBL1201151 | Study: DrugMatrix | Cell Type: liver | Dose: 250.0 mg/kg | Time: 5 d Metacetamol | ID: CHEMBL9419 | Study: DrugMatrix | Cell Type: kidney | Dose: 700.0 mg/kg | Time: 1 d Metacetamol | ID: CHEMBL9419 | Study: DrugMatrix | Cell Type: kidney | Dose: 700.0 mg/kg | Time: 3 d Metacetamol | ID: CHEMBL9419 | Study: DrugMatrix | Cell Type: kidney | Dose: 700.0 mg/kg | Time: 5 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 2 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 8 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 8 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 8 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Metformin | ID: CHEMBL1431 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 2 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 8 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 2 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 2 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Methapyrilene | ID: CHEMBL1411979 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Methapyrilene | ID: CHEMBL1411979 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 100.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 300.0 μM | Time: 16 h Methapyrilene | ID: CHEMBL1411979 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 300.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 1 d Methapyrilene | ID: CHEMBL1411979 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 3 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Methimazole | ID: CHEMBL1515 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Methimazole | ID: CHEMBL1515 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 1 d Methimazole | ID: CHEMBL1515 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 3 d Methotrexate | ID: CHEMBL426 | Study: DrugMatrix | Cell Type: kidney | Dose: 0.3 mg/kg | Time: 3 d Methotrexate | ID: CHEMBL426 | Study: DrugMatrix | Cell Type: kidney | Dose: 27.0 mg/kg | Time: 1 d Methotrexate | ID: CHEMBL426 | Study: DrugMatrix | Cell Type: kidney | Dose: 27.0 mg/kg | Time: 3 d Methotrexate | ID: CHEMBL34259 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 1 d Methyl Salicylate | ID: CHEMBL108545 | Study: DrugMatrix | Cell Type: liver | Dose: 444.0 mg/kg | Time: 6 h Methyl Salicylate | ID: CHEMBL108545 | Study: DrugMatrix | Cell Type: liver | Dose: 444.0 mg/kg | Time: 1 d Methyl Salicylate | ID: CHEMBL108545 | Study: DrugMatrix | Cell Type: liver | Dose: 444.0 mg/kg | Time: 3 d Methyl Salicylate | ID: CHEMBL108545 | Study: DrugMatrix | Cell Type: liver | Dose: 444.0 mg/kg | Time: 5 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 2 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 8 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Methyldopa | ID: CHEMBL459 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 2 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 8 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.6 μM | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 2 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 8 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.8 μM | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 2 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 2 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Methyltestosterone | ID: CHEMBL1395 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Methyltestosterone | ID: CHEMBL1395 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d Methyltestosterone | ID: CHEMBL1395 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 5 d Metoprolol | ID: CHEMBL13 | Study: DrugMatrix | Cell Type: heart | Dose: 120.0 mg/kg | Time: 1 d Metoprolol | ID: CHEMBL13 | Study: DrugMatrix | Cell Type: heart | Dose: 120.0 mg/kg | Time: 3 d Metoprolol | ID: CHEMBL13 | Study: DrugMatrix | Cell Type: heart | Dose: 120.0 mg/kg | Time: 5 d Metoprolol | ID: CHEMBL13 | Study: DrugMatrix | Cell Type: heart | Dose: 1200.0 mg/kg | Time: 5 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 3 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 6 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 9 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 3 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 6 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 9 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 3 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 6 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 9 h Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 1 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 4 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 8 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 15 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 29 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 4 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 8 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 15 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 29 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 4 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 8 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 15 d Mexiletine | ID: CHEMBL558 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 29 d Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 200.0 mg/kg | Time: 6 h Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 200.0 mg/kg | Time: 1 d Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 200.0 mg/kg | Time: 3 d Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 200.0 mg/kg | Time: 5 d Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 920.0 mg/kg | Time: 6 h Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 920.0 mg/kg | Time: 1 d Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 920.0 mg/kg | Time: 3 d Miconazole | ID: CHEMBL91 | Study: DrugMatrix | Cell Type: liver | Dose: 920.0 mg/kg | Time: 5 d Microcystin-Lr | ID: CHEMBL444092 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.07 μM | Time: 16 h Microcystin-Lr | ID: CHEMBL444092 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 0.07 μM | Time: 1 d Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 6 h Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 1 d Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 3 d Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 3.0 mg/kg | Time: 5 d Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 6 h Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 1 d Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 3 d Mifepristone | ID: CHEMBL1276308 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 5 d Mitomycin C | ID: CHEMBL105 | Study: DrugMatrix | Cell Type: liver | Dose: 0.5 mg/kg | Time: 6 h Mitomycin C | ID: CHEMBL105 | Study: DrugMatrix | Cell Type: liver | Dose: 0.5 mg/kg | Time: 5 d Mitomycin C | ID: CHEMBL105 | Study: DrugMatrix | Cell Type: liver | Dose: 1.7 mg/kg | Time: 6 h Mitomycin C | ID: CHEMBL105 | Study: DrugMatrix | Cell Type: liver | Dose: 1.7 mg/kg | Time: 1 d Mitomycin C | ID: CHEMBL105 | Study: DrugMatrix | Cell Type: liver | Dose: 1.7 mg/kg | Time: 3 d Mitomycin C | ID: CHEMBL105 | Study: DrugMatrix | Cell Type: liver | Dose: 1.7 mg/kg | Time: 5 d Mitoxantrone | ID: CHEMBL58 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 1 d Mitoxantrone | ID: CHEMBL58 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 3 d Mitoxantrone | ID: CHEMBL58 | Study: DrugMatrix | Cell Type: heart | Dose: 2.0 mg/kg | Time: 5 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 51.0 μM | Time: 16 h Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 51.0 μM | Time: 1 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: kidney | Dose: 70.0 mg/kg | Time: 1 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: kidney | Dose: 70.0 mg/kg | Time: 3 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: kidney | Dose: 70.0 mg/kg | Time: 5 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: kidney | Dose: 212.0 mg/kg | Time: 1 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: kidney | Dose: 212.0 mg/kg | Time: 3 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: kidney | Dose: 212.0 mg/kg | Time: 5 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: liver | Dose: 70.0 mg/kg | Time: 1 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: liver | Dose: 70.0 mg/kg | Time: 3 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: liver | Dose: 70.0 mg/kg | Time: 5 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: liver | Dose: 212.0 mg/kg | Time: 1 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: liver | Dose: 212.0 mg/kg | Time: 3 d Mln-518 | ID: CHEMBL124660 | Study: DrugMatrix | Cell Type: liver | Dose: 212.0 mg/kg | Time: 5 d Modafinil | ID: CHEMBL1373 | Study: DrugMatrix | Cell Type: liver | Dose: 325.0 mg/kg | Time: 3 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.6 μM | Time: 2 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.6 μM | Time: 8 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.6 μM | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 18.0 μM | Time: 2 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 18.0 μM | Time: 8 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 18.0 μM | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 90.0 μM | Time: 2 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 90.0 μM | Time: 8 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 90.0 μM | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 18.0 μM | Time: 8 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 18.0 μM | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 90.0 μM | Time: 8 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 90.0 μM | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 3 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 6 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 9 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 3.0 mg/kg | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Monocrotaline | ID: CHEMBL521035 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Monocrotaline | ID: CHEMBL469442 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 333.0 μM | Time: 16 h Monocrotaline | ID: CHEMBL469442 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 333.0 μM | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 2 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 8 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 2 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 8 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 8 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 3 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 6 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 9 h Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 1 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 4 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 8 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 15 d Moxisylyte | ID: CHEMBL159226 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 29 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 65000.0 μM | Time: 16 h N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 65000.0 μM | Time: 1 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: kidney | Dose: 140.0 mg/kg | Time: 6 h N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: kidney | Dose: 1400.0 mg/kg | Time: 1 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: kidney | Dose: 1400.0 mg/kg | Time: 3 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: kidney | Dose: 1400.0 mg/kg | Time: 5 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 140.0 mg/kg | Time: 6 h N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 140.0 mg/kg | Time: 1 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 140.0 mg/kg | Time: 3 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 140.0 mg/kg | Time: 5 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 6 h N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 1 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 3 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 700.0 mg/kg | Time: 7 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 1400.0 mg/kg | Time: 6 h N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 1400.0 mg/kg | Time: 1 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 1400.0 mg/kg | Time: 3 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 1400.0 mg/kg | Time: 5 d N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 2100.0 mg/kg | Time: 6 h N,N-Dimethylformamide | ID: CHEMBL268291 | Study: DrugMatrix | Cell Type: liver | Dose: 2100.0 mg/kg | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 7000.0 μM | Time: 16 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 7000.0 μM | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.67 mg/kg | Time: 6 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.67 mg/kg | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: kidney | Dose: 1.67 mg/kg | Time: 3 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: kidney | Dose: 34.0 mg/kg | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: kidney | Dose: 34.0 mg/kg | Time: 3 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: liver | Dose: 1.67 mg/kg | Time: 3 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: liver | Dose: 1.67 mg/kg | Time: 5 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: liver | Dose: 34.0 mg/kg | Time: 6 h N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: liver | Dose: 34.0 mg/kg | Time: 1 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: liver | Dose: 34.0 mg/kg | Time: 3 d N-Nitrosodiethylamine | ID: CHEMBL164290 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 5 d N-Nitrosodimethylamine | ID: CHEMBL117311 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 5 d Nabumetone | ID: CHEMBL1070 | Study: DrugMatrix | Cell Type: kidney | Dose: 2500.0 mg/kg | Time: 1 d Nabumetone | ID: CHEMBL1070 | Study: DrugMatrix | Cell Type: kidney | Dose: 2500.0 mg/kg | Time: 3 d Nafenopin | ID: CHEMBL1909070 | Study: DrugMatrix | Cell Type: liver | Dose: 338.0 mg/kg | Time: 1 d Nafenopin | ID: CHEMBL1909070 | Study: DrugMatrix | Cell Type: liver | Dose: 338.0 mg/kg | Time: 3 d Nafenopin | ID: CHEMBL1909070 | Study: DrugMatrix | Cell Type: liver | Dose: 338.0 mg/kg | Time: 5 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Naproxen | ID: CHEMBL154 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Naproxen | ID: CHEMBL154 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 3 d Naproxen | ID: CHEMBL154 | Study: DrugMatrix | Cell Type: kidney | Dose: 134.0 mg/kg | Time: 1 d Naproxen | ID: CHEMBL154 | Study: DrugMatrix | Cell Type: kidney | Dose: 134.0 mg/kg | Time: 3 d Naproxen | ID: CHEMBL154 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 3 d Neomycin | ID: CHEMBL184618 | Study: DrugMatrix | Cell Type: kidney | Dose: 56.0 mg/kg | Time: 6 h Neomycin | ID: CHEMBL184618 | Study: DrugMatrix | Cell Type: kidney | Dose: 56.0 mg/kg | Time: 1 d Neomycin | ID: CHEMBL184618 | Study: DrugMatrix | Cell Type: kidney | Dose: 56.0 mg/kg | Time: 3 d Neomycin | ID: CHEMBL184618 | Study: DrugMatrix | Cell Type: kidney | Dose: 56.0 mg/kg | Time: 5 d Neomycin | ID: CHEMBL184618 | Study: DrugMatrix | Cell Type: kidney | Dose: 877.0 mg/kg | Time: 5 d Neomycin | ID: CHEMBL184618 | Study: DrugMatrix | Cell Type: liver | Dose: 56.0 mg/kg | Time: 6 h Netilmycin | ID: CHEMBL1572 | Study: DrugMatrix | Cell Type: kidney | Dose: 40.0 mg/kg | Time: 5 d Netilmycin | ID: CHEMBL1572 | Study: DrugMatrix | Cell Type: kidney | Dose: 40.0 mg/kg | Time: 14 d Netilmycin | ID: CHEMBL1572 | Study: DrugMatrix | Cell Type: kidney | Dose: 41.0 mg/kg | Time: 3 d Nevirapine | ID: CHEMBL57 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 16 h Nevirapine | ID: CHEMBL57 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Nicotinic Acid | ID: CHEMBL573 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 2 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 8 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 50.0 μM | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 2 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 8 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 250.0 μM | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 8 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Nifedipine | ID: CHEMBL193 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 2 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 8 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 66.0 μM | Time: 8 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 66.0 μM | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 330.0 μM | Time: 8 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 330.0 μM | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Nimesulide | ID: CHEMBL56367 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Nimesulide | ID: CHEMBL56367 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 61.7 μM | Time: 16 h Nimesulide | ID: CHEMBL56367 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 61.7 μM | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: DrugMatrix | Cell Type: kidney | Dose: 162.0 mg/kg | Time: 1 d Nimesulide | ID: CHEMBL56367 | Study: DrugMatrix | Cell Type: kidney | Dose: 162.0 mg/kg | Time: 3 d Nimesulide | ID: CHEMBL56367 | Study: DrugMatrix | Cell Type: kidney | Dose: 162.0 mg/kg | Time: 5 d Nimesulide | ID: CHEMBL56367 | Study: DrugMatrix | Cell Type: liver | Dose: 162.0 mg/kg | Time: 3 d Nimetazepam | ID: CHEMBL13341 | Study: DrugMatrix | Cell Type: liver | Dose: 122.0 mg/kg | Time: 1 d Nimetazepam | ID: CHEMBL13341 | Study: DrugMatrix | Cell Type: liver | Dose: 122.0 mg/kg | Time: 3 d Nimetazepam | ID: CHEMBL13341 | Study: DrugMatrix | Cell Type: liver | Dose: 122.0 mg/kg | Time: 5 d Nitrazepam | ID: CHEMBL13209 | Study: DrugMatrix | Cell Type: liver | Dose: 310.0 mg/kg | Time: 3 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 2 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 8 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 2 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 8 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 125.0 μM | Time: 2 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 125.0 μM | Time: 8 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 125.0 μM | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 2 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 8 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 2 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 8 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 125.0 μM | Time: 2 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 125.0 μM | Time: 8 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 125.0 μM | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 3 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 6 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 9 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 10.0 mg/kg | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 3 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 6 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 9 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 30.0 mg/kg | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Nitrofurantoin | ID: CHEMBL572 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 2 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 8 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 300.0 μM | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Nitrofurazone | ID: CHEMBL869 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Noradrenaline | ID: CHEMBL1437 | Study: DrugMatrix | Cell Type: heart | Dose: 1.75 mg/kg | Time: 3 d Noradrenaline | ID: CHEMBL1437 | Study: DrugMatrix | Cell Type: heart | Dose: 1.75 mg/kg | Time: 5 d Norethindrone | ID: CHEMBL1162 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 16 h Norethindrone | ID: CHEMBL1162 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 1 d Norethindrone | ID: CHEMBL1162 | Study: DrugMatrix | Cell Type: liver | Dose: 0.08 mg/kg | Time: 6 h Norethindrone | ID: CHEMBL1162 | Study: DrugMatrix | Cell Type: liver | Dose: 0.08 mg/kg | Time: 1 d Norethindrone | ID: CHEMBL1162 | Study: DrugMatrix | Cell Type: liver | Dose: 0.08 mg/kg | Time: 5 d Norethindrone | ID: CHEMBL1162 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 6 h Norethindrone | ID: CHEMBL1162 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 5 d Norethindrone Acetate | ID: CHEMBL1201146 | Study: DrugMatrix | Cell Type: liver | Dose: 125.0 mg/kg | Time: 1 d Norethindrone Acetate | ID: CHEMBL1201146 | Study: DrugMatrix | Cell Type: liver | Dose: 125.0 mg/kg | Time: 3 d Norethindrone Acetate | ID: CHEMBL1201146 | Study: DrugMatrix | Cell Type: liver | Dose: 125.0 mg/kg | Time: 5 d Norfloxacin | ID: CHEMBL9 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Nortriptyline | ID: CHEMBL445 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 70.0 μM | Time: 16 h Nortriptyline | ID: CHEMBL445 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 70.0 μM | Time: 1 d Nystatin | ID: CHEMBL229383 | Study: DrugMatrix | Cell Type: kidney | Dose: 134.0 mg/kg | Time: 3 d Nystatin | ID: CHEMBL229383 | Study: DrugMatrix | Cell Type: liver | Dose: 134.0 mg/kg | Time: 3 d Olanzapine | ID: CHEMBL715 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 16 h Olanzapine | ID: CHEMBL715 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 250.0 μM | Time: 1 d Olanzapine | ID: CHEMBL715 | Study: DrugMatrix | Cell Type: liver | Dose: 23.0 mg/kg | Time: 5 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.8 μM | Time: 2 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.8 μM | Time: 8 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.8 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 2 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 8 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 2 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 8 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 24.0 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 2 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 2 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 3 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 6 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 9 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 100.0 mg/kg | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Omeprazole | ID: CHEMBL1503 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Omeprazole | ID: CHEMBL1503 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 365.0 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 400.0 μM | Time: 16 h Omeprazole | ID: CHEMBL1503 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 400.0 μM | Time: 1 d Omeprazole | ID: CHEMBL1503 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 435.0 μM | Time: 1 d Oxaliplatin | ID: CHEMBL414804 | Study: DrugMatrix | Cell Type: kidney | Dose: 8.0 mg/kg | Time: 3 d Oxaliplatin | ID: CHEMBL414804 | Study: DrugMatrix | Cell Type: kidney | Dose: 8.0 mg/kg | Time: 5 d Oxaprozin | ID: CHEMBL1071 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 3 d Oxaprozin | ID: CHEMBL1071 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Oxfendazole | ID: CHEMBL42442 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 1 d Oxybutynin | ID: CHEMBL1231 | Study: DrugMatrix | Cell Type: heart | Dose: 230.0 mg/kg | Time: 3 d Oxybutynin | ID: CHEMBL1231 | Study: DrugMatrix | Cell Type: heart | Dose: 230.0 mg/kg | Time: 5 d Oxybutynin | ID: CHEMBL1231 | Study: DrugMatrix | Cell Type: muscle | Dose: 230.0 mg/kg | Time: 3 d Oxybutynin | ID: CHEMBL1231 | Study: DrugMatrix | Cell Type: muscle | Dose: 230.0 mg/kg | Time: 5 d Oxymetazoline | ID: CHEMBL762 | Study: DrugMatrix | Cell Type: liver | Dose: 0.5 mg/kg | Time: 6 h Oxymetazoline | ID: CHEMBL762 | Study: DrugMatrix | Cell Type: liver | Dose: 0.5 mg/kg | Time: 1 d Oxymetholone | ID: CHEMBL1200585 | Study: DrugMatrix | Cell Type: liver | Dose: 1170.0 mg/kg | Time: 1 d Oxymetholone | ID: CHEMBL1200585 | Study: DrugMatrix | Cell Type: liver | Dose: 1170.0 mg/kg | Time: 3 d Oxymetholone | ID: CHEMBL1200585 | Study: DrugMatrix | Cell Type: liver | Dose: 1170.0 mg/kg | Time: 5 d Oxytetracycline | ID: CHEMBL1517 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 5 d Pantoprazole | ID: CHEMBL1502 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 650.0 μM | Time: 16 h Pantoprazole | ID: CHEMBL1502 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 650.0 μM | Time: 1 d Pantoprazole | ID: CHEMBL1502 | Study: DrugMatrix | Cell Type: liver | Dose: 1100.0 mg/kg | Time: 3 d Pantoprazole | ID: CHEMBL1502 | Study: DrugMatrix | Cell Type: liver | Dose: 1100.0 mg/kg | Time: 5 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 2 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 8 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 2 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 8 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 8 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 3 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 6 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 9 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 3 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 6 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 9 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 3 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 6 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 9 h Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 1 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 4 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 8 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 15 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 29 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 4 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 8 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 15 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 29 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 4 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 8 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 15 d Papaverine | ID: CHEMBL19224 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 29 d Paraquat Dichloride | ID: CHEMBL74469 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 650.0 μM | Time: 16 h Paraquat Dichloride | ID: CHEMBL74469 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 650.0 μM | Time: 1 d Paroxetine | ID: CHEMBL490 | Study: DrugMatrix | Cell Type: heart | Dose: 104.0 mg/kg | Time: 3 d Paroxetine | ID: CHEMBL490 | Study: DrugMatrix | Cell Type: heart | Dose: 104.0 mg/kg | Time: 5 d Paroxetine | ID: CHEMBL490 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 30.0 μM | Time: 16 h Paroxetine | ID: CHEMBL490 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 30.0 μM | Time: 1 d Paroxetine | ID: CHEMBL490 | Study: DrugMatrix | Cell Type: muscle | Dose: 104.0 mg/kg | Time: 3 d Paroxetine | ID: CHEMBL490 | Study: DrugMatrix | Cell Type: muscle | Dose: 104.0 mg/kg | Time: 5 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 2 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 8 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 75.0 μM | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 75.0 μM | Time: 8 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 75.0 μM | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 7.5 mg/kg | Time: 3 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 7.5 mg/kg | Time: 6 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 7.5 mg/kg | Time: 9 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 7.5 mg/kg | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 3 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 6 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 9 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 25.0 mg/kg | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 3 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 6 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 9 h Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 7.5 mg/kg | Time: 4 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 7.5 mg/kg | Time: 8 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 7.5 mg/kg | Time: 15 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 7.5 mg/kg | Time: 29 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 4 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 8 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 15 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 25.0 mg/kg | Time: 29 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 4 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 8 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 15 d Pemoline | ID: CHEMBL1177 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 29 d Pemoline | ID: CHEMBL1177 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 833.0 μM | Time: 16 h Pemoline | ID: CHEMBL1177 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 833.0 μM | Time: 1 d Pemoline | ID: CHEMBL1177 | Study: DrugMatrix | Cell Type: liver | Dose: 70.0 mg/kg | Time: 1 d Penciclovir | ID: CHEMBL1540 | Study: DrugMatrix | Cell Type: kidney | Dose: 1200.0 mg/kg | Time: 3 d Penciclovir | ID: CHEMBL1540 | Study: DrugMatrix | Cell Type: kidney | Dose: 1200.0 mg/kg | Time: 5 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Penicillamine | ID: CHEMBL1430 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Pentoxifylline | ID: CHEMBL628 | Study: DrugMatrix | Cell Type: heart | Dose: 1170.0 mg/kg | Time: 3 d Pentoxifylline | ID: CHEMBL628 | Study: DrugMatrix | Cell Type: heart | Dose: 1170.0 mg/kg | Time: 5 d Pentoxifylline | ID: CHEMBL628 | Study: DrugMatrix | Cell Type: muscle | Dose: 1170.0 mg/kg | Time: 3 d Pentoxifylline | ID: CHEMBL628 | Study: DrugMatrix | Cell Type: muscle | Dose: 1170.0 mg/kg | Time: 5 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 2 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 8 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 2 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 8 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 2 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 2 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Perhexiline | ID: CHEMBL75880 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Perhexiline | ID: CHEMBL75880 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 12.0 μM | Time: 16 h Perhexiline | ID: CHEMBL75880 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 12.0 μM | Time: 1 d Phalloidin | ID: CHEMBL502682 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.0 μM | Time: 16 h Phalloidin | ID: CHEMBL502682 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.0 μM | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 2 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 8 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 24.0 μM | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 2 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 8 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 120.0 μM | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 2 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 8 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 600.0 μM | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 8 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 120.0 μM | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 3 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 6 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 9 h Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Phenacetin | ID: CHEMBL16073 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Phenacetin | ID: CHEMBL16073 | Study: DrugMatrix | Cell Type: kidney | Dose: 619.0 mg/kg | Time: 1 d Phenacetin | ID: CHEMBL16073 | Study: DrugMatrix | Cell Type: kidney | Dose: 619.0 mg/kg | Time: 3 d Phenacetin | ID: CHEMBL16073 | Study: DrugMatrix | Cell Type: kidney | Dose: 619.0 mg/kg | Time: 5 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 2 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 8 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 2 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 8 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 2 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 2 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 2 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Phenobarbital | ID: CHEMBL40 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Phenobarbital | ID: CHEMBL40 | Study: DrugMatrix | Cell Type: liver | Dose: 25.0 mg/kg | Time: 6 h Phenobarbital | ID: CHEMBL40 | Study: DrugMatrix | Cell Type: liver | Dose: 25.0 mg/kg | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 1 d Phenobarbital | ID: CHEMBL40 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 3 d Phenobarbital | ID: CHEMBL40 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 5 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 8 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 40.0 μM | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 8 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 3 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 6 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 9 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 300.0 mg/kg | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 3 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 6 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 9 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 1000.0 mg/kg | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 3 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 6 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 9 h Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 2000.0 mg/kg | Time: 1 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Phenylanthranilic Acid | ID: CHEMBL23832 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 2 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 8 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 2 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 8 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 2 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 8 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 2 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 3 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 6 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 9 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 3 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 6 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 9 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 3 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 6 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 9 h Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 1 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Phenylbutazone | ID: CHEMBL101 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Phenylbutazone | ID: CHEMBL101 | Study: DrugMatrix | Cell Type: kidney | Dose: 368.0 mg/kg | Time: 3 d Phenylbutazone | ID: CHEMBL101 | Study: DrugMatrix | Cell Type: kidney | Dose: 368.0 mg/kg | Time: 5 d Phenylephrine | ID: CHEMBL1215 | Study: DrugMatrix | Cell Type: heart | Dose: 0.44 mg/kg | Time: 3 d Phenylephrine | ID: CHEMBL1215 | Study: DrugMatrix | Cell Type: heart | Dose: 0.44 mg/kg | Time: 5 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 2 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 8 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.4 μM | Time: 2 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.4 μM | Time: 8 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.4 μM | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 2 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 8 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 12.0 μM | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 2 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 8 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 60.0 μM | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 3 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 6 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 9 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 600.0 mg/kg | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 3 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 6 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 9 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1200.0 mg/kg | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 4 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 8 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 15 d Phenytoin | ID: CHEMBL16 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 600.0 mg/kg | Time: 29 d Phenytoin | ID: CHEMBL16 | Study: DrugMatrix | Cell Type: heart | Dose: 572.0 mg/kg | Time: 3 d Phenytoin | ID: CHEMBL16 | Study: DrugMatrix | Cell Type: heart | Dose: 572.0 mg/kg | Time: 5 d Phenytoin | ID: CHEMBL16 | Study: DrugMatrix | Cell Type: muscle | Dose: 572.0 mg/kg | Time: 3 d Phenytoin | ID: CHEMBL16 | Study: DrugMatrix | Cell Type: muscle | Dose: 572.0 mg/kg | Time: 5 d Piclamilast | ID: CHEMBL42126 | Study: DrugMatrix | Cell Type: liver | Dose: 17.0 mg/kg | Time: 3 d Piclamilast | ID: CHEMBL42126 | Study: DrugMatrix | Cell Type: liver | Dose: 17.0 mg/kg | Time: 5 d Pioglitazone | ID: CHEMBL595 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 3 d Pioglitazone | ID: CHEMBL595 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 3 d Pioglitazone | ID: CHEMBL595 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 5 d Piroxicam | ID: CHEMBL527 | Study: DrugMatrix | Cell Type: kidney | Dose: 14.0 mg/kg | Time: 1 d Piroxicam | ID: CHEMBL527 | Study: DrugMatrix | Cell Type: kidney | Dose: 14.0 mg/kg | Time: 5 d Poly(Allylamine Hydrochloride) | ID: CHEMBL57286 | Study: DrugMatrix | Cell Type: heart | Dose: 40.0 mg/kg | Time: 1 d Poly(Allylamine Hydrochloride) | ID: CHEMBL57286 | Study: DrugMatrix | Cell Type: heart | Dose: 40.0 mg/kg | Time: 3 d Poly(Allylamine Hydrochloride) | ID: CHEMBL57286 | Study: DrugMatrix | Cell Type: heart | Dose: 40.0 mg/kg | Time: 5 d Poly(Allylamine Hydrochloride) | ID: CHEMBL57286 | Study: DrugMatrix | Cell Type: heart | Dose: 75.0 mg/kg | Time: 3 d Poly(Allylamine Hydrochloride) | ID: CHEMBL57286 | Study: DrugMatrix | Cell Type: heart | Dose: 75.0 mg/kg | Time: 5 d Pramocaine | ID: CHEMBL1198 | Study: DrugMatrix | Cell Type: liver | Dose: 526.0 mg/kg | Time: 3 d Prednisolone | ID: CHEMBL131 | Study: DrugMatrix | Cell Type: heart | Dose: 184.0 mg/kg | Time: 1 d Prednisolone | ID: CHEMBL131 | Study: DrugMatrix | Cell Type: kidney | Dose: 184.0 mg/kg | Time: 1 d Prednisolone | ID: CHEMBL131 | Study: DrugMatrix | Cell Type: liver | Dose: 184.0 mg/kg | Time: 1 d Prednisone | ID: CHEMBL635 | Study: DrugMatrix | Cell Type: heart | Dose: 68.0 mg/kg | Time: 1 d Primidone | ID: CHEMBL856 | Study: DrugMatrix | Cell Type: liver | Dose: 750.0 mg/kg | Time: 1 d Prinomastat | ID: CHEMBL75094 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 16 h Prinomastat | ID: CHEMBL75094 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 500.0 μM | Time: 1 d Procainamide | ID: CHEMBL640 | Study: DrugMatrix | Cell Type: heart | Dose: 755.0 mg/kg | Time: 1 d Procarbazine | ID: CHEMBL1321 | Study: DrugMatrix | Cell Type: liver | Dose: 27.0 mg/kg | Time: 6 h Procarbazine | ID: CHEMBL1321 | Study: DrugMatrix | Cell Type: liver | Dose: 27.0 mg/kg | Time: 5 d Procarbazine | ID: CHEMBL1321 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 6 h Procarbazine | ID: CHEMBL1321 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 1 d Procarbazine | ID: CHEMBL1321 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 3 d Procarbazine | ID: CHEMBL1321 | Study: DrugMatrix | Cell Type: liver | Dose: 54.0 mg/kg | Time: 5 d Progesterone | ID: CHEMBL103 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 148.0 μM | Time: 16 h Progesterone | ID: CHEMBL103 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 148.0 μM | Time: 1 d Progesterone | ID: CHEMBL103 | Study: DrugMatrix | Cell Type: liver | Dose: 11.3 mg/kg | Time: 3 d Progesterone | ID: CHEMBL103 | Study: DrugMatrix | Cell Type: liver | Dose: 11.3 mg/kg | Time: 5 d Progesterone | ID: CHEMBL103 | Study: DrugMatrix | Cell Type: liver | Dose: 164.0 mg/kg | Time: 6 h Progesterone | ID: CHEMBL103 | Study: DrugMatrix | Cell Type: liver | Dose: 164.0 mg/kg | Time: 1 d Progesterone | ID: CHEMBL103 | Study: DrugMatrix | Cell Type: liver | Dose: 164.0 mg/kg | Time: 3 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.2 μM | Time: 2 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.2 μM | Time: 8 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.2 μM | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 2 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 8 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 16.0 μM | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.0 μM | Time: 8 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.0 μM | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 35.0 μM | Time: 8 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 35.0 μM | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Promethazine | ID: CHEMBL643 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Promethazine | ID: CHEMBL643 | Study: DrugMatrix | Cell Type: liver | Dose: 2.3 mg/kg | Time: 3 d Promethazine | ID: CHEMBL643 | Study: DrugMatrix | Cell Type: liver | Dose: 2.3 mg/kg | Time: 5 d Promethazine | ID: CHEMBL643 | Study: DrugMatrix | Cell Type: liver | Dose: 113.0 mg/kg | Time: 3 d Promethazine | ID: CHEMBL643 | Study: DrugMatrix | Cell Type: liver | Dose: 113.0 mg/kg | Time: 5 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 2 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 8 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 2 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 8 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 2 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 8 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 160.0 μM | Time: 2 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 160.0 μM | Time: 8 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 160.0 μM | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 2 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 8 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 2 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 8 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Propylthiouracilum | ID: CHEMBL1518 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Propylthiouracilum | ID: CHEMBL1518 | Study: DrugMatrix | Cell Type: liver | Dose: 625.0 mg/kg | Time: 1 d Propylthiouracilum | ID: CHEMBL1518 | Study: DrugMatrix | Cell Type: liver | Dose: 625.0 mg/kg | Time: 3 d Propylthiouracilum | ID: CHEMBL1518 | Study: DrugMatrix | Cell Type: liver | Dose: 625.0 mg/kg | Time: 5 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 2 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 8 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 500.0 μM | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 2 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 8 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2500.0 μM | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 12.0 mg/kg | Time: 3 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 12.0 mg/kg | Time: 6 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 12.0 mg/kg | Time: 9 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 12.0 mg/kg | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 3 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 6 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 9 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 3 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 6 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 9 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.0 mg/kg | Time: 4 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.0 mg/kg | Time: 8 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.0 mg/kg | Time: 15 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.0 mg/kg | Time: 29 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 12.0 mg/kg | Time: 4 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 12.0 mg/kg | Time: 8 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 12.0 mg/kg | Time: 15 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 12.0 mg/kg | Time: 29 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 4 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 8 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 12.0 mg/kg | Time: 3 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 12.0 mg/kg | Time: 6 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 12.0 mg/kg | Time: 9 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 12.0 mg/kg | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 40.0 mg/kg | Time: 3 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 40.0 mg/kg | Time: 6 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 40.0 mg/kg | Time: 9 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 40.0 mg/kg | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 120.0 mg/kg | Time: 3 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 120.0 mg/kg | Time: 6 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 120.0 mg/kg | Time: 9 h Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 120.0 mg/kg | Time: 1 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.0 mg/kg | Time: 4 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.0 mg/kg | Time: 8 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.0 mg/kg | Time: 15 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.0 mg/kg | Time: 29 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 12.0 mg/kg | Time: 4 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 12.0 mg/kg | Time: 8 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 12.0 mg/kg | Time: 15 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 12.0 mg/kg | Time: 29 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 40.0 mg/kg | Time: 4 d Puromycin Aminonucleoside | ID: CHEMBL1233071 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 40.0 mg/kg | Time: 8 d Pyridine | ID: CHEMBL266158 | Study: DrugMatrix | Cell Type: kidney | Dose: 223.0 mg/kg | Time: 3 d Pyridine | ID: CHEMBL266158 | Study: DrugMatrix | Cell Type: kidney | Dose: 223.0 mg/kg | Time: 5 d Pyrogallol | ID: CHEMBL307145 | Study: DrugMatrix | Cell Type: liver | Dose: 1000.0 mg/kg | Time: 1 d Pyrogallol | ID: CHEMBL307145 | Study: DrugMatrix | Cell Type: liver | Dose: 1000.0 mg/kg | Time: 3 d Pyrogallol | ID: CHEMBL307145 | Study: DrugMatrix | Cell Type: liver | Dose: 1000.0 mg/kg | Time: 5 d Quetiapine | ID: CHEMBL716 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 150.0 μM | Time: 16 h Quetiapine | ID: CHEMBL716 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 150.0 μM | Time: 1 d Quinapril | ID: CHEMBL952 | Study: DrugMatrix | Cell Type: kidney | Dose: 2500.0 mg/kg | Time: 6 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 8 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10.0 μM | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 8 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 50.0 μM | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Quinidine | ID: CHEMBL97 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Rabeprazole | ID: CHEMBL1219 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 333.0 μM | Time: 16 h Rabeprazole | ID: CHEMBL1219 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 333.0 μM | Time: 1 d Rabeprazole | ID: CHEMBL1219 | Study: DrugMatrix | Cell Type: liver | Dose: 1024.0 mg/kg | Time: 3 d Raloxifene | ID: CHEMBL81 | Study: DrugMatrix | Cell Type: liver | Dose: 6.5 mg/kg | Time: 6 h Raloxifene | ID: CHEMBL81 | Study: DrugMatrix | Cell Type: liver | Dose: 6.5 mg/kg | Time: 3 d Raloxifene | ID: CHEMBL81 | Study: DrugMatrix | Cell Type: liver | Dose: 6.5 mg/kg | Time: 5 d Raloxifene | ID: CHEMBL81 | Study: DrugMatrix | Cell Type: liver | Dose: 650.0 mg/kg | Time: 6 h Raloxifene | ID: CHEMBL81 | Study: DrugMatrix | Cell Type: liver | Dose: 650.0 mg/kg | Time: 1 d Raloxifene | ID: CHEMBL81 | Study: DrugMatrix | Cell Type: liver | Dose: 650.0 mg/kg | Time: 3 d Raloxifene | ID: CHEMBL81 | Study: DrugMatrix | Cell Type: liver | Dose: 650.0 mg/kg | Time: 5 d Ramipril | ID: CHEMBL1168 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 620.0 μM | Time: 16 h Ramipril | ID: CHEMBL1168 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 620.0 μM | Time: 1 d Ramipril | ID: CHEMBL1168 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 3 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 2 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 8 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 160.0 μM | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 2 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 8 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 800.0 μM | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 2 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 8 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4000.0 μM | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 8 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 800.0 μM | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 8 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4000.0 μM | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Ranitidine | ID: CHEMBL512 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Rifabutin | ID: CHEMBL444633 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 5 d Rifabutin | ID: CHEMBL444633 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 5 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.8 μM | Time: 2 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.8 μM | Time: 8 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.8 μM | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 14.0 μM | Time: 2 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 14.0 μM | Time: 8 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 14.0 μM | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 70.0 μM | Time: 2 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 70.0 μM | Time: 8 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 70.0 μM | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.8 μM | Time: 2 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.8 μM | Time: 8 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2.8 μM | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.0 μM | Time: 2 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.0 μM | Time: 8 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 14.0 μM | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 70.0 μM | Time: 2 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 70.0 μM | Time: 8 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 70.0 μM | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 3 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 6 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 9 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 20.0 mg/kg | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 3 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 6 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 9 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 60.0 mg/kg | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 3 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 6 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 9 h Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 200.0 mg/kg | Time: 1 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Rifampicin | ID: CHEMBL374478 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Rifampicin | ID: CHEMBL374478 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 16 h Rifampicin | ID: CHEMBL374478 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 125.0 μM | Time: 1 d Risperidone | ID: CHEMBL85 | Study: DrugMatrix | Cell Type: heart | Dose: 22.0 mg/kg | Time: 1 d Risperidone | ID: CHEMBL85 | Study: DrugMatrix | Cell Type: heart | Dose: 22.0 mg/kg | Time: 5 d Risperidone | ID: CHEMBL85 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 400.0 μM | Time: 16 h Risperidone | ID: CHEMBL85 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 400.0 μM | Time: 1 d Ritonavir | ID: CHEMBL163 | Study: DrugMatrix | Cell Type: kidney | Dose: 1200.0 mg/kg | Time: 1 d Rofecoxib | ID: CHEMBL122 | Study: DrugMatrix | Cell Type: heart | Dose: 775.0 mg/kg | Time: 3 d Rofecoxib | ID: CHEMBL122 | Study: DrugMatrix | Cell Type: heart | Dose: 775.0 mg/kg | Time: 5 d Rofecoxib | ID: CHEMBL122 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 111.0 μM | Time: 16 h Rofecoxib | ID: CHEMBL122 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 111.0 μM | Time: 1 d Rofecoxib | ID: CHEMBL122 | Study: DrugMatrix | Cell Type: kidney | Dose: 775.0 mg/kg | Time: 1 d Rofecoxib | ID: CHEMBL122 | Study: DrugMatrix | Cell Type: liver | Dose: 775.0 mg/kg | Time: 3 d Roflumilast | ID: CHEMBL193240 | Study: DrugMatrix | Cell Type: liver | Dose: 17.0 mg/kg | Time: 3 d Rolipram | ID: CHEMBL63 | Study: DrugMatrix | Cell Type: liver | Dose: 75.0 mg/kg | Time: 3 d Rolipram | ID: CHEMBL63 | Study: DrugMatrix | Cell Type: liver | Dose: 75.0 mg/kg | Time: 5 d Rosiglitazone | ID: CHEMBL121 | Study: DrugMatrix | Cell Type: liver | Dose: 1800.0 mg/kg | Time: 3 d Rosiglitazone | ID: CHEMBL121 | Study: DrugMatrix | Cell Type: liver | Dose: 1800.0 mg/kg | Time: 5 d Roxarsone | ID: CHEMBL1321154 | Study: DrugMatrix | Cell Type: kidney | Dose: 11.0 mg/kg | Time: 5 d Roxithromycin | ID: CHEMBL1214185 | Study: DrugMatrix | Cell Type: liver | Dose: 312.0 mg/kg | Time: 1 d Roxithromycin | ID: CHEMBL1214185 | Study: DrugMatrix | Cell Type: liver | Dose: 312.0 mg/kg | Time: 3 d Roxithromycin | ID: CHEMBL1214185 | Study: DrugMatrix | Cell Type: liver | Dose: 312.0 mg/kg | Time: 5 d Safrole | ID: CHEMBL242273 | Study: DrugMatrix | Cell Type: liver | Dose: 488.0 mg/kg | Time: 6 h Safrole | ID: CHEMBL242273 | Study: DrugMatrix | Cell Type: liver | Dose: 488.0 mg/kg | Time: 1 d Safrole | ID: CHEMBL242273 | Study: DrugMatrix | Cell Type: liver | Dose: 488.0 mg/kg | Time: 3 d Safrole | ID: CHEMBL242273 | Study: DrugMatrix | Cell Type: liver | Dose: 488.0 mg/kg | Time: 5 d Salicylamide | ID: CHEMBL27577 | Study: DrugMatrix | Cell Type: liver | Dose: 1300.0 mg/kg | Time: 1 d Salicylamide | ID: CHEMBL27577 | Study: DrugMatrix | Cell Type: liver | Dose: 1300.0 mg/kg | Time: 3 d Salicylic Acid | ID: CHEMBL424 | Study: DrugMatrix | Cell Type: liver | Dose: 223.0 mg/kg | Time: 1 d Salicylic Acid | ID: CHEMBL424 | Study: DrugMatrix | Cell Type: liver | Dose: 223.0 mg/kg | Time: 5 d Saquinavir | ID: CHEMBL114 | Study: DrugMatrix | Cell Type: kidney | Dose: 1500.0 mg/kg | Time: 1 d Sertraline | ID: CHEMBL809 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 23.0 μM | Time: 16 h Sertraline | ID: CHEMBL809 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 23.0 μM | Time: 1 d Sildenafil | ID: CHEMBL192 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 90.0 μM | Time: 16 h Sildenafil | ID: CHEMBL192 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 90.0 μM | Time: 1 d Sildenafil | ID: CHEMBL192 | Study: DrugMatrix | Cell Type: liver | Dose: 420.0 mg/kg | Time: 5 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 2 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 8 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 8 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 3 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 6 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 9 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 40.0 mg/kg | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 3 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 6 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 9 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 120.0 mg/kg | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 3 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 6 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 9 h Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 400.0 mg/kg | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 4 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 8 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 15 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 40.0 mg/kg | Time: 29 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 4 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 8 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 15 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 120.0 mg/kg | Time: 29 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 4 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 8 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 15 d Simvastatin | ID: CHEMBL1064 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 400.0 mg/kg | Time: 29 d Simvastatin | ID: CHEMBL1064 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 160.0 μM | Time: 16 h Simvastatin | ID: CHEMBL1064 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 160.0 μM | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: DrugMatrix | Cell Type: liver | Dose: 15.0 mg/kg | Time: 6 h Simvastatin | ID: CHEMBL1064 | Study: DrugMatrix | Cell Type: liver | Dose: 15.0 mg/kg | Time: 3 d Simvastatin | ID: CHEMBL1064 | Study: DrugMatrix | Cell Type: liver | Dose: 1200.0 mg/kg | Time: 1 d Simvastatin | ID: CHEMBL1064 | Study: DrugMatrix | Cell Type: liver | Dose: 1200.0 mg/kg | Time: 3 d Sirolimus | ID: CHEMBL413 | Study: DrugMatrix | Cell Type: heart | Dose: 60.0 mg/kg | Time: 3 d Sirolimus | ID: CHEMBL413 | Study: DrugMatrix | Cell Type: heart | Dose: 60.0 mg/kg | Time: 5 d Sirolimus | ID: CHEMBL413 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 20.0 μM | Time: 16 h Sirolimus | ID: CHEMBL413 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 20.0 μM | Time: 1 d Sirolimus | ID: CHEMBL413 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 3 d Sirolimus | ID: CHEMBL413 | Study: DrugMatrix | Cell Type: kidney | Dose: 60.0 mg/kg | Time: 5 d Sodium Arsenite | ID: CHEMBL1909078 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 6 h Sodium Arsenite | ID: CHEMBL1909078 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 1 d Sodium Arsenite | ID: CHEMBL1909078 | Study: DrugMatrix | Cell Type: kidney | Dose: 10.0 mg/kg | Time: 3 d Sodium Arsenite | ID: CHEMBL1909078 | Study: DrugMatrix | Cell Type: kidney | Dose: 30.0 mg/kg | Time: 7 d Sodium Arsenite | ID: CHEMBL1909078 | Study: DrugMatrix | Cell Type: liver | Dose: 10.0 mg/kg | Time: 6 h Sodium Arsenite | ID: CHEMBL1909078 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 3 d Sodium Arsenite | ID: CHEMBL1909078 | Study: DrugMatrix | Cell Type: liver | Dose: 30.0 mg/kg | Time: 7 d Sodium-Orthovanadate | ID: CHEMBL50626 | Study: DrugMatrix | Cell Type: kidney | Dose: 83.0 mg/kg | Time: 3 d Sodium-Orthovanadate | ID: CHEMBL50626 | Study: DrugMatrix | Cell Type: kidney | Dose: 83.0 mg/kg | Time: 5 d Sotalol | ID: CHEMBL471 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 6666.0 μM | Time: 16 h Sotalol | ID: CHEMBL471 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 6666.0 μM | Time: 1 d Sotalol | ID: CHEMBL471 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 1 d Sotalol | ID: CHEMBL471 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d Sparteine | ID: CHEMBL44625 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2222.0 μM | Time: 16 h Sparteine | ID: CHEMBL44625 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 2222.0 μM | Time: 1 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: heart | Dose: 300.0 mg/kg | Time: 1 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: heart | Dose: 300.0 mg/kg | Time: 3 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: heart | Dose: 300.0 mg/kg | Time: 5 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: kidney | Dose: 300.0 mg/kg | Time: 5 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 1 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: liver | Dose: 300.0 mg/kg | Time: 5 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: muscle | Dose: 300.0 mg/kg | Time: 3 d Spironolactone | ID: CHEMBL1393 | Study: DrugMatrix | Cell Type: muscle | Dose: 300.0 mg/kg | Time: 5 d Stannous Fluoride | ID: CHEMBL1909079 | Study: DrugMatrix | Cell Type: kidney | Dose: 90.0 mg/kg | Time: 1 d Stanozolol | ID: CHEMBL1200324 | Study: DrugMatrix | Cell Type: liver | Dose: 150.0 mg/kg | Time: 3 d Staurosporine | ID: CHEMBL290084 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.3 μM | Time: 16 h Staurosporine | ID: CHEMBL290084 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1.3 μM | Time: 1 d Stavudine | ID: CHEMBL124363 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1120.0 μM | Time: 16 h Stavudine | ID: CHEMBL124363 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1120.0 μM | Time: 1 d Stavudine | ID: CHEMBL124363 | Study: DrugMatrix | Cell Type: liver | Dose: 1400.0 mg/kg | Time: 3 d Streptomycin | ID: CHEMBL1201194 | Study: DrugMatrix | Cell Type: kidney | Dose: 120.0 mg/kg | Time: 3 d Streptomycin | ID: CHEMBL1201194 | Study: DrugMatrix | Cell Type: kidney | Dose: 120.0 mg/kg | Time: 5 d Streptozotocin | ID: CHEMBL1651906 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 3000.0 μM | Time: 16 h Streptozotocin | ID: CHEMBL1651906 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 3000.0 μM | Time: 1 d Streptozotocin | ID: CHEMBL1651906 | Study: DrugMatrix | Cell Type: liver | Dose: 138.0 mg/kg | Time: 1 d Streptozotocin | ID: CHEMBL1651906 | Study: DrugMatrix | Cell Type: liver | Dose: 138.0 mg/kg | Time: 3 d Streptozotocin | ID: CHEMBL1651906 | Study: DrugMatrix | Cell Type: liver | Dose: 138.0 mg/kg | Time: 5 d Sulbactam | ID: CHEMBL403 | Study: DrugMatrix | Cell Type: kidney | Dose: 671.0 mg/kg | Time: 5 d Sulconazole | ID: CHEMBL1221 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 40.0 μM | Time: 16 h Sulconazole | ID: CHEMBL1221 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 40.0 μM | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 2 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 8 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 4.0 μM | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 2 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 8 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 20.0 μM | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 2 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 8 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 100.0 μM | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 2 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 8 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 2 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 2 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 8 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Sulfasalazine | ID: CHEMBL421 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 8 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 600.0 μM | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3000.0 μM | Time: 8 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3000.0 μM | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 4 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 8 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 15 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 5.0 mg/kg | Time: 29 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Sulindac | ID: CHEMBL15770 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: heart | Dose: 132.0 mg/kg | Time: 3 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: heart | Dose: 132.0 mg/kg | Time: 5 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 750.0 μM | Time: 16 h Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 750.0 μM | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: kidney | Dose: 23.0 mg/kg | Time: 5 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: kidney | Dose: 64.0 mg/kg | Time: 3 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: kidney | Dose: 64.0 mg/kg | Time: 5 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: liver | Dose: 132.0 mg/kg | Time: 6 h Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: liver | Dose: 132.0 mg/kg | Time: 1 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: liver | Dose: 132.0 mg/kg | Time: 3 d Sulindac | ID: CHEMBL15770 | Study: DrugMatrix | Cell Type: liver | Dose: 132.0 mg/kg | Time: 5 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 2 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 8 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5000.0 μM | Time: 2 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5000.0 μM | Time: 8 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5000.0 μM | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 8 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 8 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 3 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 6 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 9 h Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 2000.0 mg/kg | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Sulpiride | ID: CHEMBL26 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Sulpiride | ID: CHEMBL26 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 3 d Sulpiride | ID: CHEMBL26 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 5 d Sulpiride | ID: CHEMBL26 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 667.0 μM | Time: 16 h Sulpiride | ID: CHEMBL26 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 667.0 μM | Time: 1 d Sulpiride | ID: CHEMBL26 | Study: DrugMatrix | Cell Type: muscle | Dose: 1000.0 mg/kg | Time: 3 d Sulpiride | ID: CHEMBL26 | Study: DrugMatrix | Cell Type: muscle | Dose: 1000.0 mg/kg | Time: 5 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 8 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 16.0 μM | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 8 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 80.0 μM | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 3 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 6 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 9 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 3.0 mg/kg | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 4 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 8 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 15 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 3.0 mg/kg | Time: 29 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Tacrine | ID: CHEMBL95 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Tacrine | ID: CHEMBL2171328 | Study: DrugMatrix | Cell Type: heart | Dose: 24.0 mg/kg | Time: 1 d Tacrolimus Hydrate | ID: CHEMBL269732 | Study: DrugMatrix | Cell Type: heart | Dose: 134.0 mg/kg | Time: 3 d Tacrolimus Hydrate | ID: CHEMBL269732 | Study: DrugMatrix | Cell Type: heart | Dose: 134.0 mg/kg | Time: 5 d Tacrolimus Hydrate | ID: CHEMBL269732 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 50.0 μM | Time: 16 h Tacrolimus Hydrate | ID: CHEMBL269732 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 50.0 μM | Time: 1 d Tacrolimus Hydrate | ID: CHEMBL269732 | Study: DrugMatrix | Cell Type: kidney | Dose: 134.0 mg/kg | Time: 3 d Tacrolimus Hydrate | ID: CHEMBL269732 | Study: DrugMatrix | Cell Type: kidney | Dose: 134.0 mg/kg | Time: 5 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.12 μM | Time: 2 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.12 μM | Time: 8 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.12 μM | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 8 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 8 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 3 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 6 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 9 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 6.0 mg/kg | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 4 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 8 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 15 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 6.0 mg/kg | Time: 29 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Tamoxifen | ID: CHEMBL83 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Tamoxifen | ID: CHEMBL83 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 37.5 μM | Time: 16 h Tamoxifen | ID: CHEMBL83 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 37.5 μM | Time: 1 d Tamoxifen | ID: CHEMBL83 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 3 d Tamoxifen | ID: CHEMBL83 | Study: DrugMatrix | Cell Type: liver | Dose: 2.5 mg/kg | Time: 5 d Tamoxifen | ID: CHEMBL83 | Study: DrugMatrix | Cell Type: liver | Dose: 64.0 mg/kg | Time: 3 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 2 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 8 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.0 μM | Time: 8 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.0 μM | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 8 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Tannic Acid | ID: CHEMBL506247 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Temafloxacin | ID: CHEMBL277100 | Study: DrugMatrix | Cell Type: kidney | Dose: 1000.0 mg/kg | Time: 3 d Temafloxacin | ID: CHEMBL277100 | Study: DrugMatrix | Cell Type: kidney | Dose: 1000.0 mg/kg | Time: 5 d Tenidap | ID: CHEMBL1908355 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 41.0 μM | Time: 16 h Tenidap | ID: CHEMBL1908355 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 41.0 μM | Time: 1 d Tenidap | ID: CHEMBL1908355 | Study: DrugMatrix | Cell Type: kidney | Dose: 75.0 mg/kg | Time: 6 h Tenidap | ID: CHEMBL1908355 | Study: DrugMatrix | Cell Type: kidney | Dose: 75.0 mg/kg | Time: 3 d Tenidap | ID: CHEMBL1908355 | Study: DrugMatrix | Cell Type: kidney | Dose: 75.0 mg/kg | Time: 5 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 2 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 8 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.6 μM | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 2 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 8 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3.0 μM | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 2 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 8 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 15.0 μM | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 3 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 6 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 9 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 75.0 mg/kg | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 3 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 6 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 9 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 250.0 mg/kg | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 750.0 mg/kg | Time: 3 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 750.0 mg/kg | Time: 6 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 750.0 mg/kg | Time: 9 h Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 750.0 mg/kg | Time: 1 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 4 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 8 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 15 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 75.0 mg/kg | Time: 29 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 4 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 8 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 15 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 250.0 mg/kg | Time: 29 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 750.0 mg/kg | Time: 4 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 750.0 mg/kg | Time: 8 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 750.0 mg/kg | Time: 15 d Terbinafine | ID: CHEMBL822 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 750.0 mg/kg | Time: 29 d Testosterone | ID: CHEMBL195836 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 3 d Testosterone | ID: CHEMBL195836 | Study: DrugMatrix | Cell Type: liver | Dose: 375.0 mg/kg | Time: 5 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 2 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 8 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1000.0 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 2 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 8 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 3000.0 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 2 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 8 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 300.0 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1500.0 μM | Time: 2 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1500.0 μM | Time: 8 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1500.0 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7500.0 μM | Time: 2 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7500.0 μM | Time: 8 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7500.0 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Tetrachloromethane | ID: CHEMBL44814 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 193.7 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 387.5 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 775.0 μM | Time: 16 h Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 775.0 μM | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: kidney | Dose: 400.0 mg/kg | Time: 6 h Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: kidney | Dose: 400.0 mg/kg | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: kidney | Dose: 1175.0 mg/kg | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: kidney | Dose: 1175.0 mg/kg | Time: 3 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: kidney | Dose: 1175.0 mg/kg | Time: 7 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 6 h Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 3 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 400.0 mg/kg | Time: 7 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 1175.0 mg/kg | Time: 6 h Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 1175.0 mg/kg | Time: 1 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 1175.0 mg/kg | Time: 3 d Tetrachloromethane | ID: CHEMBL44814 | Study: DrugMatrix | Cell Type: liver | Dose: 1175.0 mg/kg | Time: 7 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 2 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 8 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 2 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 8 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 2 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 8 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.0 μM | Time: 2 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.0 μM | Time: 8 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.0 μM | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 2 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 8 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5.0 μM | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 2 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 8 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 25.0 μM | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Tetracycline | ID: CHEMBL1440 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 3 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 6 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 9 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 20.0 mg/kg | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 3 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 6 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 9 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 60.0 mg/kg | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 3 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 6 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 9 h Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 200.0 mg/kg | Time: 1 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 4 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 8 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 15 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 20.0 mg/kg | Time: 29 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 4 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 8 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 15 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 60.0 mg/kg | Time: 29 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 4 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 8 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 15 d Theophylline | ID: CHEMBL190 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 200.0 mg/kg | Time: 29 d Thiabendazole | ID: CHEMBL625 | Study: DrugMatrix | Cell Type: liver | Dose: 92.0 mg/kg | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 2 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 2 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 2 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 8 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 10000.0 μM | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4.5 mg/kg | Time: 3 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4.5 mg/kg | Time: 6 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4.5 mg/kg | Time: 9 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 4.5 mg/kg | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 3 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 6 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 9 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 4 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 8 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 15 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 4.5 mg/kg | Time: 29 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 4 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 8 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 15 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 29 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 4.5 mg/kg | Time: 3 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 4.5 mg/kg | Time: 6 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 4.5 mg/kg | Time: 9 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 4.5 mg/kg | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 3 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 6 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 9 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 3 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 6 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 9 h Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 1 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.5 mg/kg | Time: 4 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.5 mg/kg | Time: 8 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.5 mg/kg | Time: 15 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 4.5 mg/kg | Time: 29 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 4 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 8 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 15 d Thioacetamide | ID: CHEMBL38737 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 29 d Thioacetamide | ID: CHEMBL38737 | Study: DrugMatrix | Cell Type: liver | Dose: 200.0 mg/kg | Time: 5 d Thioguanine | ID: CHEMBL727 | Study: DrugMatrix | Cell Type: liver | Dose: 12.0 mg/kg | Time: 6 h Thioguanine | ID: CHEMBL727 | Study: DrugMatrix | Cell Type: liver | Dose: 12.0 mg/kg | Time: 1 d Thioguanine | ID: CHEMBL727 | Study: DrugMatrix | Cell Type: liver | Dose: 12.0 mg/kg | Time: 3 d Thioguanine | ID: CHEMBL727 | Study: DrugMatrix | Cell Type: liver | Dose: 12.0 mg/kg | Time: 5 d Thioguanine | ID: CHEMBL727 | Study: DrugMatrix | Cell Type: liver | Dose: 24.0 mg/kg | Time: 3 d Thioguanine | ID: CHEMBL727 | Study: DrugMatrix | Cell Type: liver | Dose: 24.0 mg/kg | Time: 5 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 2 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 8 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 2 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 8 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 0.6 μM | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 2 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 8 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 3.0 μM | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 2 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 8 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 15.0 μM | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Thioridazine | ID: CHEMBL479 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 2 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 8 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.4 μM | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 2 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 8 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 12.0 μM | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 2 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 8 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 60.0 μM | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 8 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 4.0 μM | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 8 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 20.0 μM | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Ticlopidine | ID: CHEMBL833 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 2 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 8 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.0 μM | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 2 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 8 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 5.0 μM | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 2 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 8 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 25.0 μM | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Tiopronin | ID: CHEMBL1314 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Tobramycin | ID: CHEMBL1747 | Study: DrugMatrix | Cell Type: kidney | Dose: 40.0 mg/kg | Time: 5 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 2 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 8 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 80.0 μM | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 8 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 400.0 μM | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 8 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 2000.0 μM | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Tolbutamide | ID: CHEMBL782 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Tosufloxacin | ID: CHEMBL273348 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 3 d Tosufloxacin | ID: CHEMBL273348 | Study: DrugMatrix | Cell Type: liver | Dose: 2000.0 mg/kg | Time: 5 d Transplatin | ID: CHEMBL1386 | Study: DrugMatrix | Cell Type: kidney | Dose: 0.5 mg/kg | Time: 5 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 2 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 8 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.2 μM | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 2 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 8 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 6.0 μM | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 2 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 8 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 30.0 μM | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 3 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 6 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 9 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 15.0 mg/kg | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 3 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 6 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 9 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 15.0 mg/kg | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 3 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 6 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 9 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 50.0 mg/kg | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 3 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 6 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 9 h Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 1 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 4 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 8 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 15 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 15.0 mg/kg | Time: 29 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Triamterene | ID: CHEMBL585 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 2 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 8 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.4 μM | Time: 1 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 2 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 8 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2.0 μM | Time: 1 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 2 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 8 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10.0 μM | Time: 1 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 3 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 6 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 9 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 300.0 mg/kg | Time: 1 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 3 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 6 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 9 h Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 1000.0 mg/kg | Time: 1 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 4 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 8 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 15 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 300.0 mg/kg | Time: 29 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 4 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 8 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 15 d Triazolam | ID: CHEMBL646 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 1000.0 mg/kg | Time: 29 d Trichloroacetic Acid | ID: CHEMBL14053 | Study: DrugMatrix | Cell Type: liver | Dose: 474.0 mg/kg | Time: 1 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 3 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 6 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 9 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 50.0 mg/kg | Time: 1 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 3 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 6 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 9 h Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 500.0 mg/kg | Time: 1 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 4 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 8 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 15 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 50.0 mg/kg | Time: 29 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 4 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 8 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 15 d Trimethadione | ID: CHEMBL695 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 500.0 mg/kg | Time: 29 d Trimethadione | ID: CHEMBL695 | Study: DrugMatrix | Cell Type: heart | Dose: 535.0 mg/kg | Time: 3 d Trimethadione | ID: CHEMBL695 | Study: DrugMatrix | Cell Type: heart | Dose: 535.0 mg/kg | Time: 5 d Trimethadione | ID: CHEMBL695 | Study: DrugMatrix | Cell Type: muscle | Dose: 535.0 mg/kg | Time: 3 d Trimethadione | ID: CHEMBL695 | Study: DrugMatrix | Cell Type: muscle | Dose: 535.0 mg/kg | Time: 5 d Troglitazone | ID: CHEMBL408 | Study: DrugMatrix | Cell Type: liver | Dose: 1200.0 mg/kg | Time: 3 d Troglitazone | ID: CHEMBL408 | Study: DrugMatrix | Cell Type: liver | Dose: 1200.0 mg/kg | Time: 5 d Tropisetron | ID: CHEMBL56564 | Study: DrugMatrix | Cell Type: liver | Dose: 100.0 mg/kg | Time: 1 d Valacyclovir | ID: CHEMBL1349 | Study: DrugMatrix | Cell Type: kidney | Dose: 2000.0 mg/kg | Time: 1 d Valdecoxib | ID: CHEMBL865 | Study: DrugMatrix | Cell Type: heart | Dose: 404.0 mg/kg | Time: 3 d Valdecoxib | ID: CHEMBL865 | Study: DrugMatrix | Cell Type: heart | Dose: 404.0 mg/kg | Time: 5 d Valdecoxib | ID: CHEMBL865 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 450.0 μM | Time: 16 h Valdecoxib | ID: CHEMBL865 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 450.0 μM | Time: 1 d Valdecoxib | ID: CHEMBL865 | Study: DrugMatrix | Cell Type: kidney | Dose: 404.0 mg/kg | Time: 1 d Valdecoxib | ID: CHEMBL865 | Study: DrugMatrix | Cell Type: kidney | Dose: 404.0 mg/kg | Time: 3 d Valdecoxib | ID: CHEMBL865 | Study: DrugMatrix | Cell Type: kidney | Dose: 404.0 mg/kg | Time: 5 d Valeric Acid | ID: CHEMBL268736 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 23000.0 μM | Time: 16 h Valeric Acid | ID: CHEMBL268736 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 23000.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 2 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 8 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 400.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 2 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 8 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 2000.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 2 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 8 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 10000.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 2 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 8 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 200.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 2 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 8 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1000.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 2 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 8 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 5000.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 3 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 6 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 9 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 45.0 mg/kg | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 3 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 6 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 9 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 150.0 mg/kg | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 3 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 6 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 9 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 450.0 mg/kg | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 4 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 8 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 15 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 45.0 mg/kg | Time: 29 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 4 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 8 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 15 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 450.0 mg/kg | Time: 29 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 3 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 6 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 9 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 45.0 mg/kg | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 3 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 6 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 9 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 150.0 mg/kg | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 450.0 mg/kg | Time: 3 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 450.0 mg/kg | Time: 6 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 450.0 mg/kg | Time: 9 h Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneySingleDose | Dose: 450.0 mg/kg | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 4 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 8 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 15 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 45.0 mg/kg | Time: 29 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 4 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 8 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 15 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 150.0 mg/kg | Time: 29 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 450.0 mg/kg | Time: 4 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 450.0 mg/kg | Time: 8 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 450.0 mg/kg | Time: 15 d Valproic Acid | ID: CHEMBL109 | Study: TG-GATEs | Cell Type: inVivoRatKidneyRepeatDose | Dose: 450.0 mg/kg | Time: 29 d Valproic Acid | ID: CHEMBL109 | Study: DrugMatrix | Cell Type: heart | Dose: 1500.0 mg/kg | Time: 3 d Valproic Acid | ID: CHEMBL109 | Study: DrugMatrix | Cell Type: heart | Dose: 1500.0 mg/kg | Time: 5 d Valproic Acid | ID: CHEMBL109 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 16 h Valproic Acid | ID: CHEMBL109 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 1 d Valproic Acid | ID: CHEMBL109 | Study: DrugMatrix | Cell Type: liver | Dose: 1340.0 mg/kg | Time: 3 d Valproic Acid | ID: CHEMBL109 | Study: DrugMatrix | Cell Type: liver | Dose: 1340.0 mg/kg | Time: 5 d Valproic Acid | ID: CHEMBL109 | Study: DrugMatrix | Cell Type: liver | Dose: 1500.0 mg/kg | Time: 1 d Valsartan | ID: CHEMBL1069 | Study: DrugMatrix | Cell Type: heart | Dose: 30.0 mg/kg | Time: 6 h Valsartan | ID: CHEMBL1069 | Study: DrugMatrix | Cell Type: heart | Dose: 30.0 mg/kg | Time: 1 d Valsartan | ID: CHEMBL1069 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 1 d Valsartan | ID: CHEMBL1069 | Study: DrugMatrix | Cell Type: heart | Dose: 1000.0 mg/kg | Time: 3 d Vancomycin | ID: CHEMBL262777 | Study: DrugMatrix | Cell Type: kidney | Dose: 160.0 mg/kg | Time: 1 d Vancomycin | ID: CHEMBL262777 | Study: DrugMatrix | Cell Type: kidney | Dose: 160.0 mg/kg | Time: 3 d Vancomycin | ID: CHEMBL262777 | Study: DrugMatrix | Cell Type: kidney | Dose: 160.0 mg/kg | Time: 5 d Venlafaxine | ID: CHEMBL637 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1481.0 μM | Time: 16 h Venlafaxine | ID: CHEMBL637 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1481.0 μM | Time: 1 d Vinblastine | ID: CHEMBL159 | Study: DrugMatrix | Cell Type: heart | Dose: 0.3 mg/kg | Time: 3 d Vinblastine | ID: CHEMBL159 | Study: DrugMatrix | Cell Type: heart | Dose: 0.3 mg/kg | Time: 5 d Vinblastine | ID: CHEMBL159 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 45.0 μM | Time: 16 h Vinblastine | ID: CHEMBL159 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 45.0 μM | Time: 1 d Vinblastine | ID: CHEMBL159 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 1 d Vinblastine | ID: CHEMBL159 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 3 d Vinblastine | ID: CHEMBL159 | Study: DrugMatrix | Cell Type: liver | Dose: 0.3 mg/kg | Time: 5 d Vinorelbine | ID: CHEMBL607994 | Study: DrugMatrix | Cell Type: heart | Dose: 1.5 mg/kg | Time: 3 d Vinorelbine | ID: CHEMBL607994 | Study: DrugMatrix | Cell Type: heart | Dose: 1.5 mg/kg | Time: 5 d Vinorelbine | ID: CHEMBL607994 | Study: DrugMatrix | Cell Type: liver | Dose: 1.5 mg/kg | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.3 μM | Time: 2 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.3 μM | Time: 8 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 0.3 μM | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.5 μM | Time: 2 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.5 μM | Time: 8 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 1.5 μM | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.5 μM | Time: 2 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.5 μM | Time: 8 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 7.5 μM | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.5 μM | Time: 8 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 1.5 μM | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.5 μM | Time: 8 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 7.5 μM | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Vitamin A | ID: CHEMBL986 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 2 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 8 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 8.0 μM | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 2 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 8 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 40.0 μM | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 2 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 8 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroRatLiver | Dose: 200.0 μM | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 2 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 8 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 6.0 μM | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 2 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 8 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 30.0 μM | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 2 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 8 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVitroHumanLiver | Dose: 150.0 μM | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 3 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 6 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 9 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 10.0 mg/kg | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 3 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 6 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 9 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 30.0 mg/kg | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 3 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 6 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 9 h Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverSingleDose | Dose: 100.0 mg/kg | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 4 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 8 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 15 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 10.0 mg/kg | Time: 29 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 4 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 8 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 15 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 30.0 mg/kg | Time: 29 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 4 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 8 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 15 d Wy-14643 | ID: CHEMBL295416 | Study: TG-GATEs | Cell Type: inVivoRatLiverRepeatDose | Dose: 100.0 mg/kg | Time: 29 d Wy-14643 | ID: CHEMBL295416 | Study: DrugMatrix | Cell Type: liver | Dose: 364.0 mg/kg | Time: 1 d Wy-14643 | ID: CHEMBL295416 | Study: DrugMatrix | Cell Type: liver | Dose: 364.0 mg/kg | Time: 3 d Wy-14643 | ID: CHEMBL295416 | Study: DrugMatrix | Cell Type: liver | Dose: 364.0 mg/kg | Time: 5 d Zidovudine | ID: CHEMBL129 | Study: DrugMatrix | Cell Type: heart | Dose: 1540.0 mg/kg | Time: 5 d Zidovudine | ID: CHEMBL129 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 16 h Zidovudine | ID: CHEMBL129 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 1000.0 μM | Time: 1 d Zidovudine | ID: CHEMBL129 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 14800.0 μM | Time: 16 h Zidovudine | ID: CHEMBL129 | Study: DrugMatrix | Cell Type: hepatocyte | Dose: 14800.0 μM | Time: 1 d Zileuton | ID: CHEMBL93 | Study: DrugMatrix | Cell Type: liver | Dose: 450.0 mg/kg | Time: 3 d Zomepirac | ID: CHEMBL19490 | Study: DrugMatrix | Cell Type: kidney | Dose: 11.0 mg/kg | Time: 1 d Zomepirac | ID: CHEMBL19490 | Study: DrugMatrix | Cell Type: liver | Dose: 11.0 mg/kg | Time: 6 h Zomepirac | ID: CHEMBL19490 | Study: DrugMatrix | Cell Type: liver | Dose: 11.0 mg/kg | Time: 1 d Zomepirac | ID: CHEMBL19490 | Study: DrugMatrix | Cell Type: liver | Dose: 11.0 mg/kg | Time: 3 d Zomepirac | ID: CHEMBL19490 | Study: DrugMatrix | Cell Type: liver | Dose: 11.0 mg/kg | Time: 5 d